U.S. patent application number 14/877569 was filed with the patent office on 2016-06-09 for combination therapy of anti-her3 antibodies.
This patent application is currently assigned to HOFFMANN-LA ROCHE INC.. The applicant listed for this patent is Hoffmann-La Roche Inc.. Invention is credited to Frieder Bauss, Birgit Bossenmaier, Thomas Friess, Christian Gerdes, Max Hasmann, Marlene Thomas, Martin Weisser.
Application Number | 20160159912 14/877569 |
Document ID | / |
Family ID | 47504772 |
Filed Date | 2016-06-09 |
United States Patent
Application |
20160159912 |
Kind Code |
A1 |
Bauss; Frieder ; et
al. |
June 9, 2016 |
COMBINATION THERAPY OF ANTI-HER3 ANTIBODIES
Abstract
The present invention relates to the combination therapy of
anti-HER3 antibodies with certain anti-HER antibodies.
Inventors: |
Bauss; Frieder; (Neuhofen,
DE) ; Bossenmaier; Birgit; (Seefeld, DE) ;
Friess; Thomas; (Diessen-Dettenhofen, DE) ; Gerdes;
Christian; (Erlenbach, CH) ; Hasmann; Max;
(Muenchen, DE) ; Thomas; Marlene; (Penzberg,
DE) ; Weisser; Martin; (Penzberg, DE) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Hoffmann-La Roche Inc. |
Little Falls |
NJ |
US |
|
|
Assignee: |
HOFFMANN-LA ROCHE INC.
Little Falls
NJ
|
Family ID: |
47504772 |
Appl. No.: |
14/877569 |
Filed: |
October 7, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14151626 |
Jan 9, 2014 |
9180185 |
|
|
14877569 |
|
|
|
|
Current U.S.
Class: |
424/133.1 |
Current CPC
Class: |
C07K 2317/41 20130101;
A61K 39/3955 20130101; A61K 2039/505 20130101; C07K 16/2863
20130101; A61P 15/00 20180101; C07K 2317/76 20130101; C07K 2317/73
20130101; C07K 16/3015 20130101; A61K 2039/507 20130101; A61P 35/00
20180101; A61P 43/00 20180101; A61P 1/18 20180101; C07K 2317/732
20130101; C07K 2317/92 20130101; C07K 2317/24 20130101; A61P 13/08
20180101; A61P 1/00 20180101; C07K 16/32 20130101; C07K 2317/565
20130101 |
International
Class: |
C07K 16/28 20060101
C07K016/28; C07K 16/30 20060101 C07K016/30; C07K 16/32 20060101
C07K016/32 |
Foreign Application Data
Date |
Code |
Application Number |
Jan 11, 2013 |
EP |
13151076.0 |
Claims
1. A method of treating a patient suffering from a HER2-normal
cancer wherein the method comprises the administration of an
antibody which binds to human HER3 in combination with an antibody
which binds to human HER2 and which inhibits dimerization of
HER2.
2. The method of claim 1, wherein the antibody which binds to human
HER3 comprises a heavy chain variable domain comprising a CDR3H
region of SEQ ID NO: 1, a CDR2H region of SEQ ID NO: 2, and a CDR1H
region of SEQ ID NO:3, and a light chain variable domain comprising
a CDR3L region of SEQ ID NO: 4, a CDR2L region of SEQ ID NO:5, and
a CDR1L region of SEQ ID NO:6 or a CDR1L region of SEQ ID NO:7.
3. The method of claim 1, wherein the antibody which binds to human
HER3 is characterized in that the heavy chain variable domain
comprises a CDR3H region of SEQ ID NO: 1, a CDR2H region of SEQ ID
NO: 2, and a CDR1H region of SEQ ID NO:3, and the light chain
variable domain comprises a CDR3L region of SEQ ID NO: 4, a CDR2L
region of SEQ ID NO:5, and a CDR1L region of SEQ ID NO:7.
4. The method of claim 1, wherein the antibody which binds to human
HER3 is characterized in that the heavy chain variable domain VH is
SEQ ID NO:8; and the light chain variable domain VL is SEQ ID
NO:10.
5. The method of claim 1, wherein the antibody which binds to human
HER3 is characterized in that it is glycosylated with a sugar chain
at Asn297 whereby the amount of fucose within said sugar chain is
65% or lower.
6. The method of claim 1, wherein the antibody which binds to human
HER2 and which inhibits dimerization of HER2 is pertuzumab.
7. The method of claim 1, wherein the cancer is characterized by a
HER3 expression.
8. The method of claim 1, wherein the cancer is breast cancer,
ovarian cancer, gastric cancer, prostate cancer, pancreatic cancer
or cancer of the head or neck breast cancer.
9. A method of treating a patient suffering from a cancer, wherein
the method comprises the administration of An an antibody which
binds to human HER3 in combination with an antibody which binds to
human HER1, wherein at least one of the antibody which binds to
human HER3 and the antibody which binds to human HER1 is
characterized in that the antibody is glycosylated with a sugar
chain at Asn297 whereby the amount of fucose within said sugar
chain is 65% or lower.
10. The method of claim 9, wherein both the antibody which binds to
human HER3 and the antibody which binds to human HER1, are
characterized in being glycosylated with a sugar chain at Asn297
whereby the amount of fucose within said sugar chain is 65% or
lower.
11. The method of claim 9, wherein the antibody which binds to
human HER3 comprises a heavy chain variable domain comprising a
CDR3H region of SEQ ID NO: 1, a CDR2H region of SEQ ID NO: 2, and a
CDR1H region of SEQ ID NO:3, and a light chain variable domain
comprising a CDR3L region of SEQ ID NO: 4, a CDR2L region of SEQ ID
NO:5, and a CDR1L region of SEQ ID NO:7.
12. The method of claim 9, wherein the antibody which binds to
human HER3 is characterized in that the heavy chain variable domain
VH is SEQ ID NO:8; and the light chain variable domain VL is SEQ ID
NO:10.
13. The method of claim 9, wherein the antibody which binds to
human HER1 is characterized in that the heavy chain variable domain
VH is SEQ ID NO:20; and the light chain variable domain VL is SEQ
ID NO:21.
14. The method of claim 12, wherein the antibody which binds to
human HER1 is characterized in that the heavy chain variable domain
VH is SEQ ID NO:20; and the light chain variable domain VL is SEQ
ID NO:21.
15. The method of claim 9, wherein the cancer is characterized by a
HER3 expression.
16. The method of claim 15, wherein the cancer is characterized by
a HER1 expression.
17. The method of claim 9, wherein the cancer is lung cancer or
breast cancer, colorectal cancer, or head and neck cancer.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 14/151,626 filed on Jan. 9, 2014, now U.S. Pat. No. 9,180,185,
which claims priority to European Patent Application No. EP
13151076.0 filed Jan. 11, 2013, the disclosures of both of which
are incorporated herein by reference in their entirety.
SEQUENCE LISTING
[0002] The present application contains a Sequence Listing which
has been submitted in ASCII format via EFS-Web and is hereby
incorporated by reference in its entirety. Said ASCII copy, created
on Jan. 7, 2014, is named P5733US_ST25.txt and is 54,072 bytes in
size.
FIELD OF THE INVENTION
[0003] The present invention relates to the combination therapy of
anti-HER3 antibodies with certain anti-HER antibodies.
BACKGROUND OF THE INVENTION
[0004] Human HER3 (ErbB-3, ERBB3, c-erbB-3,c-erbB3, receptor
tyrosine-protein kinase erbB-3, SEQ ID NO: 17) encodes a member of
the epidermal growth factor receptor (EGFR) family of receptor
tyrosine kinases which also includes HER1 (also known as EGFR),
HER2, and HER4 (Kraus, M. H. et al, PNAS 86 (1989) 9193-9197;
Plowman, G. D. et al, PNAS 87 (1990) 4905-4909; Kraus, M. H. et al,
PNAS 90 (1993) 2900-2904). Like the prototypical epidermal growth
factor receptor, the transmembrane receptor HER3 consists of an
extracellular ligand-binding domain (ECD), a dimerization domain
within the ECD, a transmembrane domain, an intracellular protein
tyrosine kinase domain (TKD) and a C-terminal phosphorylation
domain. This membrane-bound protein has HER3 a Heregulin (HRG)
binding domain within the extracellular domain but not an active
kinase domain. It therefore can bind this ligand but not convey the
signal into the cell through protein phosphorylation. However, it
does form heterodimers with other HER family members which do have
kinase activity. Heterodimerization leads to the activation of the
receptor-mediated signaling pathway and transphosphorylation of its
intracellular domain. Dimer formation between HER family members
expands the signaling potential of HER3 and is a means not only for
signal diversification but also signal amplification. For example
the HER2/HER3 heterodimer induces one of the most important
mitogenic signals via the PI3K and AKT pathway among HER family
members (Sliwkowski M. X., et al, J. Biol. Chem. 269 (1994)
14661-14665; Alimandi M, et al, Oncogene. 10 (1995) 1813-1821;
Hellyer, N.J., J. Biol. Chem. 276 (2001) 42153-4261; Singer, E., J.
Biol. Chem. 276 (2001) 44266-44274; Schaefer, K. L., Neoplasia 8
(2006) 613-622).
[0005] Expression of this gene and/or expression of its protein
have been reported in numerous cancers, including prostate,
bladder, and breast tumors. Alternate transcriptional splice
variants encoding different isoforms have been characterized. One
isoform lacks the intermembrane region and is secreted outside the
cell. This form acts to modulate the activity of the membrane-bound
form. Additional splice variants have also been reported, but they
have not been thoroughly characterized.
[0006] WO 97/35885 relates to HER3 antibodies. WO 2003/013602
relates to inhibitors of HER activity, including HER antibodies. WO
2007/077028, WO 2008/100624, WO2011076683, WO2011044311,
WO2011136911, WO2012019024, WO2012022814, WO2012031198,
WO2012044612, WO2012052230, WO2012059858 relate to HER3
antibodies.
[0007] Human HER2 refers to 185-kDa growth factor receptor also
referred to as neu and c-erbB-2 (Slamon, et al., Science 235 (1987)
177-182; Swiss-Prot P04626) whose function is related to neoplastic
transformation in human breast cancer cells. Overexpression of this
protein has been identified in 20-30% of breast cancer patients
where it correlates with regionally advanced disease, increased
probability of tumor recurrence, and reduced patient survival. As
many as 30-40% of patients having gastric, endometrial, salivary
gland, non-small cell lung, pancreatic, ovarian, peritoneal,
prostate, or colorectal cancers may also exhibit overexpression of
this protein.
[0008] The HER receptor will generally comprise an extracellular
domain, which may bind an HER ligand; a lipophilic transmembrane
domain, a conserved intracellular tyrosine kinase domain, and a
carboxyl-terminal signaling domain harboring several tyrosine
residues which can be phosphorylated. The extracellular domain of
HER2 comprises four domains, Domain I (amino acid residues from
about 1-195), Domain II (amino acid residues from about 196-320),
Domain III (amino acid residues from about 321 488), and Domain IV
(amino acid residues from about 489-632) (residue numbering without
signal peptide). See Garrett, et al., Mol. Cell. 11 (2003) 495-505,
Cho, et al., Nature 421 (2003) 756-760, Franklin, et al., Cancer
Cell 5 (2004) 317-328, or Plowman, et al., Proc. Natl. Acad. Sci.
90 (1993) 1746-1750 and WO 2006/007398.
[0009] Trastuzumab (sold under the tradename Herceptin.RTM.) is a
recombinant humanized anti-HER2 monoclonal antibody used for the
treatment of HER2 over-expressed/HER2 gene amplified metastatic
breast cancer. Trastuzumab binds specifically to the same epitope
of HER2 as the murine anti-HER2 antibody 4D5 described in Hudziak,
et al., Mol. Cell. BioL 9 (1989) 1165-1172. Trastuzumab is a
recombinant humanized version of the murine anti-HER2 antibody 4D5,
referred to as rhuMAb 4D5 or trastuzumab) and has been clinically
active in patients with HER2-overexpressing metastatic breast
cancers that had received extensive prior anticancer therapy.
(Baselga, et al, J. Clin. Oncol. 14 (1996) 737-744). Trastuzumab
and its method of preparation are described in U.S. Pat. No.
5,821,337.
[0010] Pertuzumab (Omnitarg.RTM.) is another recombinant humanized
anti-HER2 monoclonal antibody used for the treatment of HER2
positive cancers. Pertuzumab binds specifically to the 2C4 epitope,
a different epitope on the extracellular domain of HER2 as
trastuzumab. Pertuzumab is the first in a new class of HER2
dimerisation inhibitors (HDIs). Through its binding to the HER2
extracellular domain, pertuzumab inhibits dimerization of HER2
(with other HER family members), thereby inhibiting downstream
signalling pathways and cellular processes associated with tumour
growth and progression (Franklin, M. C., et al. Cancer Cell 5
(2004) 317-328 and Friess, T, et al. Clin Cancer Res 11 (2005)
5300-5309). Pertuzumab is a recombinant humanized version of the
murine anti-HER2 antibody 2C4 (referred to as rhuMAb 2C4 or
pertuzumab) and it is described together with the respective method
of preparation in WO 01/00245 and WO 2006/007398.
[0011] The "epitope 2C4" is the region in the extracellular domain
of HER2 to which the antibody 2C4 binds. In order to screen for
antibodies which bind to the 2C4 epitope, a routine cross-blocking
assay such as that described in "Ed. Harlow and David Lane,
Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory,
(1988)", can be performed. Alternatively, epitope mapping can be
performed to assess whether the antibody binds to the 2C4 epitope
of HER2 (e.g. any one or more residues in the region from about
residue 22 to about residue 584 of HER2, inclusive). Epitope 2C4
comprises residues from domain II in the extracellular domain of
HER2. 2C4 and pertuzumab bind to the extracellular domain of HER2
at the junction of domains I, II and III. See also Franklin, et
al., Cancer Cell 5 (2004) 317-328.
[0012] Human HER1 (also known as r Erb-B1 or Human epidermal growth
factor receptor (EGFR) (SEQ ID NO: 19) is a 170 kDa transmembrane
receptor encoded by the c-erbB proto-oncogene, and exhibits
intrinsic tyrosine kinase activity (Modjtahedi, H., et al., Br. J.
Cancer 73 (1996) 228-235; Herbst, R. S., and Shin, D. M., Cancer 94
(2002) 1593-1611). SwissProt database entry P00533 provides the
sequence of EGFR. There are also isoforms and variants of EGFR
(e.g., alternative RNA transcripts, truncated versions,
polymorphisms, etc.) including but not limited to those identified
by Swissprot database entry numbers P00533-1, P00533-2, P00533-3,
and P00533-4. EGFR is known to bind ligands including epidermal
growth factor (EGF), transforming growth factor-.alpha.
(TGf-.alpha.), amphiregulin, heparin-binding EGF (hb-EGF),
betacellulin, and epiregulin (Herbst, R. S., and Shin, D. M.,
Cancer 94 (2002) 1593-1611; Mendelsohn, J., and Baselga, J.,
Oncogene 19 (2000) 6550-6565). EGFR regulates numerous cellular
processes via tyrosine-kinase mediated signal transduction
pathways, including, but not limited to, activation of signal
transduction pathways that control cell proliferation,
differentiation, cell survival, apoptosis, angiogenesis,
mitogenesis, and metastasis (Atalay, G., et al., Ann. Oncology 14
(2003) 1346-1363; Tsao, A. S., and Herbst, R. S., Signal 4 (2003)
4-9; Herbst, R. S., and Shin, D. M., Cancer 94 (2002) 1593-1611;
Modjtahedi, H., et al., Br. J. Cancer 73 (1996) 228-235).
[0013] Overexpression of HER1 has been reported in numerous human
malignant conditions, including cancers of the bladder, brain, head
and neck, pancreas, lung, breast, ovary, colon, prostate, and
kidney. (Atalay, G., et al., Ann. Oncology 14 (2003) 1346-1363;
Herbst, R. S., and Shin, D. M., Cancer 94 (2002) 1593-1611;
Modjtahedi, H., et al., Br. J. Cancer 73 (1996) 228-235). In many
of these conditions, the overexpression of EGFR correlates or is
associated with poor prognosis of the patients. (Herbst R. S., and
Shin, D. M., Cancer 94 (2002) 1593-1611; Modjtahedi, H., et al.,
Br. J. Cancer 73 (1996) 228-235). HER1 is also expressed in the
cells of normal tissues, particularly the epithelial tissues of the
skin, liver, and gastrointestinal tract, although at generally
lower levels than in malignant cells (Herbst, R. S., and Shin, D.
M., Cancer 94 (2002) 1593-1611).
[0014] WO 2006/082515 refers to humanized anti-EGFR monoclonal
antibodies derived from the rat monoclonal antibody ICR62 and to
their glycoengineered forms for cancer therapy.
SUMMARY OF THE INVENTION
[0015] The invention provides a combination therapy of an anti-HER3
antibody with an antibody which binds to human HER2 and which
inhibits dimerization of HER2, or with an antibody which binds to
HER1, wherein the antibody which binds to human HER1, is
characterized in being glycosylated with a sugar chain at Asn297
whereby the amount of fucose within said sugar chain is 65% or
lower. In one embodiment the antibody which binds to human HER3 is
further characterized in that is glycosylated with a sugar chain at
Asn297 whereby the amount of fucose within said sugar chain is 65%
or lower.
[0016] In one aspect of the invention is an antibody which binds to
human HER3 for use in the treatment of cancer in combination with
an antibody which binds to human HER2 and which inhibits
dimerization of HER2, wherein the cancer is a HER2-normal cancer.
[0017] In one embodiment the antibody which binds to human HER3 is
characterized in that the heavy chain variable domain comprises a
CDR3H region of SEQ ID NO: 1, a CDR2H region of SEQ ID NO: 2, and a
CDR1H region of SEQ ID NO:3, and the light chain variable domain
comprises a CDR3L region of SEQ ID NO: 4, a CDR2L region of SEQ ID
NO:5, and a CDR1L region of SEQ ID NO:6 or a CDR1L region of SEQ ID
NO:7. [0018] In one embodiment the antibody which binds to human
HER3 is characterized in comprising as heavy chain variable domain
a CDR3H region of SEQ ID NO: 1, a CDR2H region of SEQ ID NO: 2, and
a CDR1H region of SEQ ID NO:3, and the light chain variable domain
comprises a CDR3L region of SEQ ID NO: 4, a CDR2L region of SEQ ID
NO:5, and a CDR1L region of SEQ ID NO:7. [0019] In one embodiment
the antibody which binds to human HER3 is characterized in that the
heavy chain variable domain VH is SEQ ID NO:8; and the light chain
variable domain VL is SEQ ID NO:10.
[0020] In one embodiment the antibody which binds to human HER3
described above is further characterized in that is glycosylated
with a sugar chain at Asn297 whereby the amount of fucose within
said sugar chain is 65% or lower.
[0021] In one embodiment the antibody which binds to human HER2 and
which inhibits dimerization of HER2 is pertuzumab.
[0022] In one embodiment the cancer is characterized by a HER3
expression.
[0023] In one embodiment the cancer is breast cancer, ovarian
cancer, gastric cancer, prostate cancer, pancreatic cancer or
cancer of the head or neck breast cancer.
[0024] Surprisingly it was found that the combination therapy an
anti-HER3 antibody described above with an antibody which binds to
human HER2 and which inhibits dimerization of HER2 showed strong
tumor growth inhibition of HER2 normal expressing cancers, even in
tumors where the an antibody which binds to human HER2 and which
inhibits dimerization of HER2, only showed low to medium tumor
growth inhibition when administered alone.
[0025] Another aspect of the invention is an antibody which binds
to human HER3 for use in the treatment of cancer in combination
with an antibody which binds to human HER1, wherein at least one of
the antibody which binds to human HER3 and the antibody which binds
to human HER1 is characterized in that the antibody is glycosylated
with a sugar chain at Asn297 whereby the amount of fucose within
said sugar chain is 65% or lower.
[0026] In one embodiment, both, the antibody which binds to human
HER3 and the antibody which binds to human HER1, are characterized
in being glycosylated with a sugar chain at Asn297 whereby the
amount of fucose within said sugar chain is 65% or lower.
[0027] In one embodiment the antibody which binds to human HER3 is
characterized in comprising as heavy chain variable domain a CDR3H
region of SEQ ID NO: 1, a CDR2H region of SEQ ID NO: 2, and a CDR1H
region of SEQ ID NO:3, and the light chain variable domain
comprises a CDR3L region of SEQ ID NO: 4, a CDR2L region of SEQ ID
NO:5, and a CDR1L region of SEQ ID NO:7.
[0028] In one embodiment the antibody which binds to human HER3 is
characterized in that the heavy chain variable domain VH is SEQ ID
NO:8; and the light chain variable domain VL is SEQ ID NO:10.
[0029] In one embodiment the antibody which binds to human HER1 is
characterized in that the heavy chain variable domain VH is SEQ ID
NO:20; and the light chain variable domain VL is SEQ ID NO:21.
[0030] In one embodiment the cancer is characterized by a HER3
expression.
[0031] In one embodiment the cancer is further characterized by a
HER1 expression.
[0032] In one embodiment the cancer is lung cancer or breast
cancer, colorectal cancer, or head and neck cancer (in one
embodiment characterized by a HER3 and HER1 expression).
[0033] Surprisingly it was found that the combination therapy an
anti-HER3 antibody described above with an antibody which binds to
human HER1 wherein at least one of the antibody which binds to
human HER3 and the antibody which binds to human HER1 is
characterized in that the antibody is glycosylated with a sugar
chain at Asn297 whereby the amount of fucose within said sugar
chain is 65% or lower, showed strong tumor growth inhibition, even
in tumors where the antibody which binds to human HER1 only showed
low to medium tumor growth inhibition when administered alone.
DESCRIPTION OF THE FIGURES
[0034] FIGS. 1A and B: Percent (%) inhibition of anti-HER3
antibodies on receptor phosphorylation in MCF7 cells in different
concentrations.
[0035] FIG. 1C Percent (%) inhibition of anti-HER3 antibodies on
receptor phosphorylation in Mel-Juso cells in different
concentrations.
[0036] FIG. 2 Treatment with Mab 205 (10 mg/kg q7dx3, i.p.)
resulted in tumor stasis of head and neck cancer FaDu SCCHN
transplanted xenografts.
[0037] FIG. 3 Treatment with Mab 205 (10 mg/kg q7d, i.p.) resulted
in tumor stasis of HER2-normal MAXF449 breast cancer transplanted
xenografts.
[0038] FIG. 4 Treatment with Mab 205 (25 mg/kg q7d, i.p.) resulted
in tumor stasis of 7177 NSCLC transplanted xenografts.
[0039] FIG. 5 Treatment of HER2-normal breast cancer cell ZR-75-1
xenografts with Mab 205.10.2 in combination with pertuzumab
resulted in tumor growth inhibition.
[0040] FIG. 6 In vivo efficacy of RG7116 in SCID-beige mice (n=10
per group) bearing BxPC3 human pancreatic adenocarcinoma
subcutaneous xenografts. (A) Mice were treated with five weekly
i.p. doses of RG7116 beginning on Day 24 and tumor size measured by
caliper. RG7116 at 0.3 mg/kg and above was highly efficacious and
significantly inhibited tumor growth. Mice were sacrificed on day
56 and explanted tumor tissue was examined by Western blotting for
expression of HER3 and pHER3 (B) and for HER3 expression by
immunohistochemistry (C). Efficacious doses of RG7116 inhibited
HER3 phosphorylation and down-modulated membrane HER3 levels.
[0041] FIG. 7 Tumor growth inhibition mediated by HER3 signal
inhibition. (A) NSCLC cell lines or patient-derived tumor tissue
fragments established as s.c. xenografts in SCID-beige or Balb/c
nude mice (n=10 per group) and treated with 4-6 weekly doses of
RG7116 (10-25 mg/kg). Substantial TGI was seen in squamous lung
models shown as black bars (including complete remission in half
the xenograft models examined) and in adenocarcinoma models shown
as grey bars (* indicates c-Met high overexpressing models,
.dagger. indicates KRAS-mutant models). (B) Time course for one of
the patient-derived squamous tumor xenografts (LXFE772) in which
complete remission was achieved with 6 cycles of 22 mg/kg RG7116.
Tumors were undetectable by Day 95. Combination of RG7116 with
other anti-HER antibodies enhanced efficacy. Complete tumor
regression was achieved when RG7116 was combined with GA201 (a
glycoengineered anti-HER1 antibody (EGFR)) in an s.c. head and neck
xenograft model (FaDu cells; FIG. 7C) and with pertuzumab
(anti-HER2) in an s.c. patient-derived breast cancer tumor
xenografts model MAXF 449 (FIG. 7D).
DETAILED DESCRIPTION OF THE INVENTION
[0042] The invention comprises an antibody which binds to human
HER3, characterized in that the heavy chain variable domain
comprises a CDR3H region of SEQ ID NO: 1, a CDR2H region of SEQ ID
NO: 2, and a CDR1H region of SEQ ID NO:3, and the light chain
variable domain comprises a CDR3L region of SEQ ID NO: 4, a CDR2L
region of SEQ ID NO:5, and a CDR1L region of SEQ ID NO:6 or a CDR1L
region of SEQ ID NO:7 for use in the combination therapies
described herein.
[0043] The invention further comprises an antibody according to the
invention characterized in that the heavy chain variable domain VH
is SEQ ID NO:8; and the light chain variable domain VL is SEQ ID
NO:9, or the light chain variable domain VL is SEQ ID NO:10, or the
light chain variable domain VL is SEQ ID NO:11; or a humanized
version thereof for use in the combination therapies described
herein.
[0044] The invention further comprises an antibody according to the
invention characterized in that the heavy chain variable domain VH
is SEQ ID NO:8; and the light chain variable domain VL is SEQ ID
NO:9, or the light chain variable domain VL is SEQ ID NO:10, or the
light chain variable domain VL is SEQ ID NO:11 for use in the
combination therapies described herein.
[0045] In one embodiment the antibody according to the invention is
characterized in comprising as heavy chain variable domain a CDR3H
region of SEQ ID NO: 1, a CDR2H region of SEQ ID NO: 2, and a CDR1H
region of SEQ ID NO:3, and the light chain variable domain
comprises a CDR3L region of SEQ ID NO: 4, a CDR2L region of SEQ ID
NO:5, and a CDR1L region of SEQ ID NO:6 for use in the combination
therapies described herein.
[0046] In one embodiment the antibody according to the invention is
characterized in that the heavy chain variable domain VH is SEQ ID
NO:8; and the light chain variable domain VL is SEQ ID NO:9 or the
light chain variable domain VL is SEQ ID NO:11 for use in the
combination therapies described herein.
[0047] In one embodiment the antibody according to the invention is
characterized in comprising as heavy chain variable domain a CDR3H
region of SEQ ID NO: 1, a CDR2H region of SEQ ID NO: 2, and a CDR1H
region of SEQ ID NO:3, and the light chain variable domain
comprises a CDR3L region of SEQ ID NO: 4, a CDR2L region of SEQ ID
NO:5, and a CDR1L region of SEQ ID NO:7 for use in the combination
therapies described herein.
[0048] In one embodiment the antibody according to the invention is
characterized in that the heavy chain variable domain VH is SEQ ID
NO:8; and the light chain variable domain VL is SEQ ID NO:10 for
use in the combination therapies described herein.
[0049] In one embodiment such antibody is monoclonal. In one
embodiment such antibody is humanized or human. In one embodiment
such antibody is of IgG1 or IgG4 subclass. In one embodiment such
antibody is a monoclonal humanized antibody of IgG1 subclass. In
one embodiment such antibody is characterized in that said antibody
is glycosylated with a sugar chain at Asn297 whereby the amount of
fucose within said sugar chain is 65% or lower.
[0050] The invention comprises the humanized antibodies Mab
205.10.1, Mab 205.10.2 and Mab 205.10.3 with their respective VH
and VL or CDRs for use in the combination therapies described
herein.
TABLE-US-00001 Antibody VH VL Mab 205.10.1 SEQ ID NO: 8 SEQ ID NO:
9 Mab 205.10.2 SEQ ID NO: 8 SEQ ID NO: 10 Mab 205.10.3 SEQ ID NO: 8
SEQ ID NO: 11 Antibody CDR3H CDR2H CDR1H CDR3L CDR2L CDR1L Mab SEQ
ID SEQ ID SEQ ID SEQ ID SEQ ID SEQ ID 205.10.1 NO: 1 NO: 2 NO: 3
NO: 4 NO: 5 NO: 6 Mab SEQ ID SEQ ID SEQ ID SEQ ID SEQ ID SEQ ID
205.10.2 NO: 1 NO: 2 NO: 3 NO: 4 NO: 5 NO: 7 Mab SEQ ID SEQ ID SEQ
ID SEQ ID SEQ ID SEQ ID 205.10.3 NO: 1 NO: 2 NO: 3 NO: 4 NO: 5 NO:
6
[0051] In one embodiment such antibodies comprise constant regions
of human origin e.g. SEQ ID NO:12-16, preferably of SEQ ID
NO:12-13.
[0052] The term "antibody" encompasses the various forms of
antibody structures including, but not being limited to, whole
antibodies and antibody fragments. The antibody according to the
invention is preferably a human antibody, humanized antibody,
chimeric antibody, or further genetically engineered antibody as
long as the characteristic properties according to the invention
are retained.
[0053] "Antibody fragments" comprise a portion of a full length
antibody, preferably the variable domain thereof, or at least the
antigen binding site thereof. Examples of antibody fragments
include diabodies, single-chain antibody molecules, and
multispecific antibodies formed from antibody fragments. scFv
antibodies are, e.g., described in Huston, J. S., Methods in
Enzymol. 203 (1991) 46-88. In addition, antibody fragments comprise
single chain polypeptides having the characteristics of a V.sub.H
domain, namely being able to assemble together with a V.sub.L
domain, or of a V.sub.L domain binding to the respective antigen
being able to assemble together with a V.sub.H domain to a
functional antigen binding site and thereby providing the
properties of an antibody according to the invention.
[0054] The terms "monoclonal antibody" or "monoclonal antibody
composition" as used herein refer to a preparation of antibody
molecules of a single amino acid composition.
[0055] The term "chimeric antibody" refers to a monoclonal antibody
comprising a variable region, i.e., binding region, from mouse and
at least a portion of a constant region derived from a different
source or species, usually prepared by recombinant DNA techniques.
Chimeric antibodies comprising a mouse variable region and a human
constant region are especially preferred. Such rat/human chimeric
antibodies are the product of expressed immunoglobulin genes
comprising DNA segments encoding rat immunoglobulin variable
regions and DNA segments encoding human immunoglobulin constant
regions. Other forms of "chimeric antibodies" encompassed by the
present invention are those in which the class or subclass has been
modified or changed from that of the original antibody. Such
"chimeric" antibodies are also referred to as "class-switched
antibodies." Methods for producing chimeric antibodies involve
conventional recombinant DNA and gene transfection techniques now
well known in the art. See, e.g., Morrison, S. L., et al., Proc.
Natl. Acad Sci. USA 81 (1984) 6851-6855; U.S. Pat. No. 5,202,238
and U.S. Pat. No. 5,204,244.
[0056] The term "humanized antibody" or "humanized version of an
antibody" refers to antibodies in which the framework or
"complementarity determining regions" (CDR) have been modified to
comprise the CDR of an immunoglobulin of different specificity as
compared to that of the parent immunoglobulin. In a preferred
embodiment, the CDRs of the VH and VL are grafted into the
framework region of human antibody to prepare the "humanized
antibody." See e.g. Riechmann, L., et al., Nature 332 (1988)
323-327; and Neuberger, M. S., et al., Nature 314 (1985) 268-270.
The heavy and light chain variable framework regions can be derived
from the same or different human antibody sequences. The human
antibody sequences can be the sequences of naturally occurring
human antibodies. Human heavy and light chain variable framework
regions are listed e.g. in Lefranc, M.-P., Current Protocols in
Immunology (2000)--Appendix 1P A.1P.1-A.1P.37 and are accessible
via IMGT, the international ImMunoGeneTics information System.RTM..
Optionally the framework region can be modified by further
mutations. Particularly preferred CDRs correspond to those
representing sequences recognizing the antigens noted above for
chimeric antibodies. Preferably such humanized version is
chimerized with a human constant region (see e.g. Sequences SEQ ID
NO:12-16). The term "humanized antibody" as used herein also
comprises such antibodies which are modified in the constant region
to generate the properties according to the invention, especially
in regard to C1q binding and/or FcR binding, e.g. by "class
switching" i.e. change or mutation of Fc parts (e.g. from IgG1 to
IgG4 and/or IgG1/IgG4 mutation).
[0057] The term "human antibody", as used herein, is intended to
include antibodies having variable and constant regions derived
from human germ line immunoglobulin sequences. Human antibodies are
well-known in the state of the art (van Dijk, M. A., and van de
Winkel, J. G., Curr. Opin. Chem. Biol. 5 (2001) 368-374). Human
antibodies can also be produced in transgenic animals (e.g., mice)
that are capable, upon immunization, of producing a full repertoire
or a selection of human antibodies in the absence of endogenous
immunoglobulin production. Transfer of the human germ-line
immunoglobulin gene array in such germ-line mutant mice will result
in the production of human antibodies upon antigen challenge (see,
e.g., Jakobovits, A., et al., Proc. Natl. Acad. Sci. USA 90 (1993)
2551-2555; Jakobovits, A., et al., Nature 362 (1993) 255-258;
Brueggemann, M. D., et al., Year Immunol. 7 (1993) 33-40). Human
antibodies can also be produced in phage display libraries
(Hoogenboom, H. R., and Winter, G., J. Mol. Biol. 227 (1992)
381-388; Marks, J. D., et al., J. Mol. Biol. 222 (1991) 581-597).
The techniques of Cole, A., et al. and Boerner, P., et al. are also
available for the preparation of human monoclonal antibodies (Cole,
A., et al., Monoclonal Antibodies and Cancer Therapy, Liss, A. L.,
p. 77 (1985); and Boerner, P., et al., J. Immunol. 147 (1991)
86-95). As already mentioned for and humanized antibodies according
to the invention the term "human antibody" as used herein also
comprises such antibodies which are modified in the constant region
to generate the properties according to the invention, especially
in regard to C1q binding and/or FcR binding, e.g. by "class
switching" i.e. change or mutation of Fc parts (e.g. from IgG1 to
IgG4 and/or IgG1/IgG4 mutation).
[0058] The term "recombinant human antibody", as used herein, is
intended to include all human antibodies that are prepared,
expressed, created or isolated by recombinant means, such as
antibodies isolated from a host cell such as a NS0 or CHO cell or
from an animal (e.g. a mouse) that is transgenic for human
immunoglobulin genes or antibodies expressed using a recombinant
expression vector transfected into a host cell. Such recombinant
human antibodies have variable and constant regions in a rearranged
form. The recombinant human antibodies according to the invention
have been subjected to in vivo somatic hypermutation. Thus, the
amino acid sequences of the VH and VL regions of the recombinant
antibodies are sequences that, while derived from and related to
human germ line VH and VL sequences, may not naturally exist within
the human antibody germ line repertoire in vivo.
[0059] As used herein, the terms "which binds to human HER3",
"which specifically binds to human HER3", or "anti-HER3 antibody"
are interchangeable and refer to an antibody which specifically
binds to the human HER3 antigen with a binding affinity of KD-value
of 1.0.times.10.sup.-8 mol/1 or lower at 25.degree. C., in one
embodiment of a KD-value of 1.0.times.10.sup.-9 mol/1 or lower at
25.degree. C. The binding affinity is determined with a standard
binding assay at 25.degree. C., such as surface plasmon resonance
technique (BIAcore.RTM., GE-Healthcare Uppsala, Sweden). A method
for determining the KD-value of the binding affinity is described
in Example 2b). Thus an "antibody which binds to human HER3" as
used herein refers to an antibody specifically which binds to the
human HER3 antigen with a binding affinity of KD
1.0.times.10.sup.-8 mol/1 or lower (in one embodiment of KD
1.0.times.10.sup.-8 mol/1-1.0.times.10.sup.-13 mol/1) at 25.degree.
C.
[0060] As used herein, the terms "which binds to human HER2",
"which specifically binds to human HER2", or "anti-HER2 antibody"
are interchangeable and refer to an antibody which specifically
binds to the human HER2 antigen with a binding affinity of KD-value
of 1.0.times.10.sup.-8 mol/1 or lower at 25.degree. C., in one
embodiment of a KD-value of 1.0.times.10.sup.-9 mol/1 or lower at
25.degree. C. The binding affinity is determined with a standard
binding assay at 25.degree. C., such as surface plasmon resonance
technique (BIAcore.RTM., GE-Healthcare Uppsala, Sweden). A method
for determining the KD-value of the binding affinity is described
in Example 2b). Thus an "antibody which binds to human HER2" as
used herein refers to an antibody specifically which binds to the
human HER2 antigen with a binding affinity of KD
1.0.times.10.sup.-8 mol/1 or lower (in one embodiment of KD
1.0.times.10.sup.-8 mol/1-1.0.times.10.sup.-13 mol/1) at 25.degree.
C.
[0061] The pairing of HER receptors on the cell surface is referred
to as dimerization. HER2 dimerizes with the other members of the
HER family, including HER1, HER3, and HER4; HER2:HER3 dimerization
is believed to produce the strongest mitogenic signaling and
activate 2 key pathways that regulate cell survival and growth
(Mitogen-activated protein kinase (MAPK) pathway and
Phosphoinositide 3-kinase (PI3K) pathway). As used herein, the term
"an antibody which binds to human HER2 and which inhibits
dimerization of HER2" refer to an anti-HER2 antibody which
specifically binds to the human HER2 antigen and which
inhibits/blocks ligand-dependent HER2 heterodimerization with HER1,
HER3, and HER4, and especially inhibits HER2/HER3 dimerization (see
e.g. PERJETA Prescribing Information. Genentech, Inc. June 2012.
Baselga J, et al; N Engl J Med. 2012; 366:109-119; Baselga J, et al
Nat Rev Cancer. 2009; 9:463-475; Hynes N E, et al Nat Rev Cancer.
2005; 5:341-354; Yarden Y, et al, Nat Rev Mol Cell Biol. 2001;
2:127-137; Hsieh A C, et al, Br J Cancer. 2007; 97:453-457; Soltoff
S P, et al, Mol Cell Biol. 1994; 14:3550-3558). Examples of such
anti-HER2 antibodies which inhibit HER2 dimerization are described
e.g. in WO 01/00245 and WO 2006/007398 wherein pertuzumab (referred
to as rhuMAb 2C4 or pertuzumab) is described as one example.
[0062] As used herein, the terms "which binds to human HER1",
"which specifically binds to human HER1", or "anti-HER1 antibody"
are interchangeable and refer to an antibody which specifically
binds to the human HER2 antigen with a binding affinity of KD-value
of 1.0.times.10.sup.-8 mol/1 or lower at 25.degree. C., in one
embodiment of a KD-value of 1.0.times.10.sup.-9 mol/1 or lower at
25.degree. C. The binding affinity is determined with a standard
binding assay at 25.degree. C., such as surface plasmon resonance
technique (BIAcore.RTM., GE-Healthcare Uppsala, Sweden). A method
for determining the KD-value of the binding affinity is described
in Example 2b). Thus an "antibody which binds to human HER2" as
used herein refers to an antibody specifically which binds to the
human HER2 antigen with a binding affinity of KD
1.0.times.10.sup.-8 mol/1 or lower (in one embodiment of KD
1.0.times.10.sup.-8 mol/1-1.0.times.10.sup.-13 mol/1) at 25.degree.
C.
[0063] Human HER3 (ErbB-3, ERBB3, c-erbB-3,c-erbB3, receptor
tyrosine-protein kinase erbB-3, SEQ ID NO: 17 including signal
peptide) encodes a member of the epidermal growth factor receptor
(EGFR) family of receptor tyrosine kinases which also includes HER1
(also known as EGFR), HER2, and HER4 (Kraus, M. H. et al, PNAS 86
(1989), 9193-9197; Plowman, G. D. et al, PNAS 87 (1990), 4905-4909;
Kraus, M. H. et al, PNAS 90 (1993), 2900-2904). Like the
prototypical epidermal growth factor receptor, the transmembrane
receptor HER3 consists of an extracellular ligand-binding domain
(ECD), a dimerization domain within the ECD, a transmembrane
domain, an intracellular protein tyrosine kinase domain (TKD) and a
C-terminal phosphorylation domain. This membrane-bound protein has
HER3 a Heregulin (HRG) binding domain within the extracellular
domain but not an active kinase domain. It therefore can bind this
ligand but not convey the signal into the cell through protein
phosphorylation. However, it does form heterodimers with other HER
family members which do have kinase activity. Heterodimerization
leads to the activation of the receptor-mediated signaling pathway
and transphosphorylation of its intracellular domain. Dimer
formation between HER family members expands the signaling
potential of HER3 and is a means not only for signal
diversification but also signal amplification. For example the
HER2/HER3 heterodimer induces one of the most important mitogenic
signals via the PI3K and AKT pathway among HER family members
(Sliwkowski, M. X., et al, J. Biol. Chem. 269 (1994) 14661-14665;
Alimandi, M., et al, Oncogene 10 (1995) 1813-1821; Hellyer, N.J.,
J. Biol. Chem. 276 (2001) 42153-421561; Singer, E., J. Biol. Chem.
276 (2001) 44266-44274; Schaefer, K. L., Neoplasia 8 (2006)
613-622).
[0064] HER3 antibodies Mab205.10.1, Mab205.10.2, and Mab205.10.3
showed a competitive binding with the ligand Heregulin (HRG) to
HER3.
[0065] Expression of this gene and/or expression of its protein
have been reported in numerous cancers, including prostate,
bladder, and breast tumors. Alternate transcriptional splice
variants encoding different isoforms have been characterized. One
isoform lacks the intermembrane region and is secreted outside the
cell. This form acts to modulate the activity of the membrane-bound
form. Additional splice variants have also been reported, but they
have not been thoroughly characterized.
[0066] The term "human HER2" according to the invention refers to
185-kDa growth factor receptor also referred to as neu and c-erbB-2
(Slamon, et al., Science 235 (1987) 177-182; Swiss-Prot P04626; SEQ
ID NO:18 including signal peptide) whose function is related to
neoplastic transformation in human breast cancer cells. The HER
receptor will generally comprise an extracellular domain, which may
bind an HER ligand; a lipophilic transmembrane domain, a conserved
intracellular tyrosine kinase domain, and a carboxyl-terminal
signaling domain harboring several tyrosine residues which can be
phosphorylated. The extracellular domain of HER2 comprises four
domains, Domain I (amino acid residues from about 1-195), Domain II
(amino acid residues from about 196-320), Domain III (amino acid
residues from about 321 488), and Domain IV (amino acid residues
from about 489-632) (residue numbering without signal peptide). See
Garrett, et al., Mol. Cell. 11 (2003) 495-505, Cho, et al., Nature
421 (2003) 756-760, Franklin, et al., Cancer Cell 5 (2004) 317-328,
or Plowman, et al., Proc. Natl. Acad. Sci. 90 (1993) 1746-1750 and
WO 2006/007398.
[0067] Pertuzumab (Omnitarg.RTM.) is another recombinant humanized
anti-HER2 monoclonal antibody used for the treatment of HER2
positive cancers. Pertuzumab binds specifically to the 2C4 epitope,
a different epitope on the extracellular domain of HER2 as
trastuzumab. Pertuzumab is the first in a new class of HER
dimerisation inhibitors (HDIs). Through its binding to the HER2
extracellular domain, pertuzumab inhibits dimerization of HER2
(especially ligand-activated heterodimerization with other HER
family members), thereby inhibiting downstream signalling pathways
and cellular processes associated with tumour growth and
progression (Franklin, M. C., et al. Cancer Cell 5 (2004) 317-328
and Friess, T, et al. Clin Cancer Res 11 (2005) 5300-5309).
Pertuzumab is a recombinant humanized version of the murine
anti-HER2 antibody 2C4 (referred to as rhuMAb 2C4 or pertuzumab)
and it is described together with the respective method of
preparation in WO 01/00245 and WO 2006/007398.
[0068] The "epitope 2C4" is the region in the extracellular domain
of HER2 to which the antibody 2C4 binds. In order to screen for
antibodies which bind to the 2C4 epitope, a routine cross-blocking
assay such as that described in "Ed. Harlow and David Lane,
Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory,
(1988)", can be performed. Alternatively, epitope mapping can be
performed to assess whether the antibody binds to the 2C4 epitope
of HER2 (e.g. any one or more residues in the region from about
residue 22 to about residue 584 of HER2, inclusive). Epitope 2C4
comprises residues from domain II in the extracellular domain of
HER2. 2C4 and pertuzumab bind to the extracellular domain of HER2
at the junction of domains I, II and III. See also Franklin, et
al., Cancer Cell 5 (2004) 317-328.
[0069] The term "human HER1" (also known as r Erb-B1 or Human
epidermal growth factor receptor (EGFR) (SEQ ID NO:19 including
signal peptide)) is a 170 kDa transmembrane receptor encoded by the
c-erbB proto-oncogene, and exhibits intrinsic tyrosine kinase
activity (Modjtahedi, H., et al., Br. J. Cancer 73 (1996) 228-235;
Herbst, R. S., and Shin, D. M., Cancer 94 (2002) 1593-1611).
SwissProt database entry P00533 provides the sequence of EGFR.
There are also isoforms and variants of HER1 (e.g., alternative RNA
transcripts, truncated versions, polymorphisms, etc.) including but
not limited to those identified by Swissprot database entry numbers
P00533-1, P00533-2, P00533-3, and P00533-4. HER1 is known to bind
ligands including epidermal growth factor (EGF), transforming
growth factor-.alpha. (TGf-.alpha.), amphiregulin, heparin-binding
EGF (hb-EGF), betacellulin, and epiregulin (Herbst, R. S., and
Shin, D. M., Cancer 94 (2002) 1593-1611; Mendelsohn, J., and
Baselga, J., Oncogene 19 (2000) 6550-6565). HER1 regulates numerous
cellular processes via tyrosine-kinase mediated signal transduction
pathways, including, but not limited to, activation of signal
transduction pathways that control cell proliferation,
differentiation, cell survival, apoptosis, angiogenesis,
mitogenesis, and metastasis (Atalay, G., et al., Ann. Oncology 14
(2003) 1346-1363; Tsao, A. S., and Herbst, R. S., Signal 4 (2003)
4-9; Herbst, R. S., and Shin, D. M., Cancer 94 (2002) 1593-1611;
Modjtahedi, H., et al., Br. J. Cancer 73 (1996) 228-235).
[0070] WO 2006/082515 refers to humanized anti-HER1 monoclonal
antibodies derived from the rat monoclonal antibody ICR62 and to
their glycoengineered forms for cancer therapy. One examples of
such humanized, glycoengineered antibodies derived from the rat
monoclonal antibody ICR62 is GA201 (described in WO 2006/082515).
GA201 is a glycoengineered anti-HER1 antibodies characterized in
comprising as heavy chain variable domain VH the amino acid
sequence of SEQ ID NO: 20 (heavy chain variable domain VH,
humanized <EGF>ICR62-I-HHD) and in comprising as light chain
variable domain VL the amino acid sequence of SEQ ID NO: 21 (light
chain variable domain VL, humanized <EGFR>ICR62-I-KC) and
further characterized in that said antibody is glycosylated with a
sugar chain at Asn297 whereby the amount of fucose within said
sugar chain is 65% or lower.
[0071] The term "epitope" includes any polypeptide determinant
capable of specific binding to an antibody. In certain embodiments,
epitope determinant include chemically active surface groupings of
molecules such as amino acids, sugar side chains, phosphoryl, or
sulfonyl, and, in certain embodiments, may have specific three
dimensional structural characteristics, and or specific charge
characteristics. An epitope is a region of an antigen that is bound
by an antibody.
[0072] The "variable domain of an antibody according to the
invention" (variable domain of a light chain (V.sub.L), variable
domain of a heavy chain (V.sub.H)) as used herein denotes each of
the pair of light and heavy chain domains which are involved
directly in binding the antibody to the antigen. The variable light
and heavy chain domains have the same general structure and each
domain comprises four framework (FR) regions whose sequences are
widely conserved, connected by three "hypervariable regions" (or
complementary determining regions, CDRs). The framework regions
adopt a .beta.-sheet conformation and the CDRs may form loops
connecting the .beta.-sheet structure. The CDRs in each chain are
held in their three-dimensional structure by the framework regions
and form together with the CDRs from the other chain the antigen
binding site. The antibody's heavy and light chain CDR3 regions
play a particularly important role in the binding
specificity/affinity of the antibodies according to the invention
and therefore provide a further object of the invention.
[0073] The term "antigen-binding portion of an antibody" when used
herein refer to the amino acid residues of an antibody which are
responsible for antigen-binding. The antigen-binding portion of an
antibody comprises amino acid residues from the "complementary
determining regions" or "CDRs". The term "antigen-binding portion"
of an antibody of the invention contains six complementarity
determining regions (CDRs) which contribute in varying degrees to
the affinity of the binding site for antigen. There are three heavy
chain variable domain CDRs (CDRH1, CDRH2 and CDRH3) and three light
chain variable domain CDRs (CDRL1, CDRL2 and CDRL3). The term
"CDRH1" denotes the CDR1 region of the heavy chain variable region
calculated according to Kabat. CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3
mean the respective regions from the heavy (H) or light (L) chain.
The extent of CDR and framework regions (FRs) is determined by
comparison to a compiled database of amino acid sequences in which
those regions have been defined according to variability among the
sequences according to Kabat et al, Sequences of Proteins of
Immunological Interest, 5th Ed. Public Health Service, National
Institutes of Health, Bethesda, Md. (1991).
[0074] The "Fe part" of an antibody is not involved directly in
binding of an antibody to an antigen, but exhibit various effector
functions. A "Fe part of an antibody" is a term well known to the
skilled artisan and defined on the basis of papain cleavage of
antibodies. Depending on the amino acid sequence of the constant
region of their heavy chains, antibodies or immunoglobulins are
divided in the classes: IgA, IgD, IgE, IgG and IgM, and several of
these may be further divided into subclasses (isotypes), e.g. IgG1,
IgG2, IgG3, and IgG4, IgA1, and IgA2. According to the heavy chain
constant regions the different classes of immunoglobulins are
called .alpha., .delta., .epsilon., .gamma., and .mu.,
respectively. The Fc part of an antibody is directly involved in
ADCC (antibody-dependent cell-mediated cytotoxicity) and CDC
(complement-dependent cytotoxicity) based on complement activation,
C1q binding and Fc receptor binding. The term "complement-dependent
cytotoxicity (CDC)" denotes a process initiated by binding of
complement factor C1q to the Fc part of most IgG antibody
subclasses. Binding of C1q to an antibody is caused by defined
protein-protein interactions at the so called binding site. Such
binding sites are known in the state of the art and described e.g.
by Boackle, R. J., et al., Nature 282 (1979) 742-743, Lukas, T. J.,
et al., J. Immunol. 127 (1981) 2555-2560, Brunhouse, R., and Cebra,
J. J., Mol. Immunol. 16 (1979) 907-917, Burton, D. R., et al.,
Nature 288 (1980) 338-344, Thommesen, J. E., et al., Mol. Immunol.
37 (2000) 995-1004, Idusogie, E. E., et al., J. Immunol. 164 (2000)
4178-4184, Hezareh, M., et al., J. Virology 75 (2001) 12161-12168,
Morgan, A., et al., Immunology 86 (1995) 319-324, EP 0 307 434.
Such binding sites are e.g. L234, L235, D270, N297, E318, K320,
K322, P331 and P329 (numbering according to EU index of Kabat, E.
A., see below). Antibodies of subclass IgG1, IgG2 and IgG3 usually
show complement activation and C1q and C3 binding, whereas IgG4 do
not activate the complement system and do not bind C1q and C3.
[0075] In one embodiment the antibody according to the invention
comprises a Fc part derived from human origin and preferably all
other parts of the human constant regions. As used herein the term
"Fc part derived from human origin" denotes a Fc part which is
either a Fc part of a human antibody of the subclass IgG1, IgG2,
IgG3 or IgG4, e.g. a Fc part from human IgG1 subclass, a mutated Fc
part from human IgG1 subclass (preferably with a mutation on
L234A+L235A), a Fc part from human IgG4 subclass or a mutated Fc
part from human IgG4 subclass (preferably with a mutation on
S228P). Preferred are the human heavy chain constant regions of SEQ
ID NO: 13 (human IgG1 subclass), SEQ ID NO: 14 (human IgG1 subclass
with mutations L234A and L235A).
[0076] In one embodiment the antibody according to the invention is
of human IgG1 subclass or of human IgG3 subclass. In one embodiment
the antibody according to the invention is of human IgG1
subclass.
[0077] In one embodiment the antibody according to the invention is
characterized in that the constant chains are of human origin. Such
constant chains are well known in the state of the art and e.g.
described by Kabat, E. A., (see e.g. Johnson, G. and Wu, T. T.,
Nucleic Acids Res. 28 (2000) 214-218). For example, a useful human
heavy chain constant region comprises an amino acid sequence of SEQ
ID NO: 13. For example, a useful human light chain constant region
comprises an amino acid sequence of a kappa-light chain constant
region of SEQ ID NO: 12.
[0078] The term "amino acid" as used within this application
denotes the group of naturally occurring carboxy .alpha.-amino
acids comprising alanine (three letter code: ala, one letter code:
A), arginine (arg, R), asparagine (asn, N), aspartic acid (asp, D),
cysteine (cys, C), glutamine (gln, Q), glutamic acid (glu, E),
glycine (gly, G), histidine (his, H), isoleucine (ile, I), leucine
(leu, L), lysine (lys, K), methionine (met, M), phenylalanine (phe,
F), proline (pro, P), serine (ser, S), threonine (thr, T),
tryptophan (trp, W), tyrosine (tyr, Y), and valine (val, V).
[0079] The terms "nucleic acid" or "nucleic acid molecule", as used
herein, are intended to include DNA molecules and RNA molecules. A
nucleic acid molecule may be single-stranded or double-stranded,
but preferably is double-stranded DNA. A nucleic acid is "operably
linked" when it is placed into a functional relationship with
another nucleic acid. For example, DNA for a presequence or
secretory leader is operable linked to DNA for a polypeptide if it
is expressed as a preprotein that participates in the secretion of
the polypeptide; a promoter or enhancer is operable linked to a
coding sequence if it affects the transcription of the sequence; or
a ribosome binding site is operable linked to a coding sequence if
it is positioned so as to facilitate translation. Generally,
"operable linked" means that the DNA sequences being linked are
colinear, and, in the case of a secretory leader, contiguous and in
reading frame. However, enhancers do not have to be contiguous.
Linking is accomplished by ligation at convenient restriction
sites. If such sites do not exist, synthetic oligonucleotide
adaptors or linkers are used in accordance with conventional
practice. As used herein, the expressions "cell", "cell line", and
"cell culture" are used interchangeably and all such designations
include progeny. Thus, the words "transformants" and "transformed
cells" include the primary subject cell and cultures derived there
from without regard for the number of transfers. It is also
understood that all progeny may not be precisely identical in DNA
content, due to deliberate or inadvertent mutations. Variant
progeny that have the same function or biological activity as
screened for in the originally transformed cell are included.
[0080] The anti-HER3 antibody described herein is preferably
characterized in that the constant chains are of human origin. Such
constant chains are well known in the state of the art and
described, e.g., by Kabat et al., Sequences of Proteins of
Immunological Interest, 5th ed., Public Health Service, National
Institutes of Health, Bethesda, Md. (1991). For example, a useful
human light chain constant region comprises an amino acid sequence
of a kappa-light chain constant region of SEQ ID NO:12. For
example, useful human heavy chain constant region comprises SEQ ID
NO:13 to 16.
[0081] In another aspect, an anti-HER3 antibody for the respective
combination therapy is provided, wherein the antibody comprises a
VH as in any of the embodiments provided above, and a VL as in any
of the embodiments provided above. In one embodiment, the antibody
comprises the VH and VL sequences in SEQ ID NO:8 and SEQ ID NO:10,
respectively; and having one or more of the following properties
(determined in assays as described in Example 3 and 2): [0082] the
anti-HER3 antibody inhibits the HER3 phosphorylation in tumor cells
such as MCF7 cells, FaDu cells or Mel-Juso cell (in one embodiment
the anti-HER3 antibody shows an inhibition of the HER3
phosphorylation in MCF7 cells of at least 80% (in one embodiment at
least 90%) at a concentration of 1.0 .mu.g/ml; in one embodiment
the anti-HER3 antibody shows an inhibition of the HER3
phosphorylation in FaDu cells of at least 80% (in one embodiment at
least 90%) at a concentration of 0.1 .mu.g/ml; in one embodiment
the anti-HER3 antibody shows an inhibition of the HER3
phosphorylation in Mel-Juso cells of at least 60% (in one
embodiment at least 70%) at a concentration of 0.1 .mu.g/ml) [0083]
the anti-HER3 antibody inhibits the AKT phosphorylation in tumor
cells such as Mel-Juso cell (in one embodiment the anti-HER3
antibody inhibits the AKT phosphorylation in Mel-Juso cells with an
IC50 value of less than 0.50 .mu.g/ml, in one embodiment with IC50
value of less than 0.35 .mu.g/ml) [0084] the anti-HER3 antibody
inhibits the proliferation of tumor cells such as MDA-MB-175 cells
(in one embodiment the anti-HER3 antibody inhibits the
proliferation of MDA-MB-175 cells with an IC50 value of less than
10 .mu.g/ml) [0085] the anti-HER3 antibody binds to HER3 with a KD
value of less than 5.0.times.10.sup.-9M, in one embodiment with a
KD value of less than 3.0.times.10.sup.-9M.
[0086] In another aspect, an anti-HER3 antibody for the respective
combination therapy is a bispecific anti-HER3/anti-HER1 antibody as
described in US 2010/0255010. In one embodiment, the bispecific
anti-HER3/anti-HER1 antibody is characterized comprising by the
characteristic amino acid sequences disclosed in US 2010/0255010,
i.e. A) (a) HVR-H1 comprising the amino acid sequence of LSGDWIH;
(b) HVR-H2 comprising the amino acid sequence of VGEISAAGGYTD; and
(c) HVR-H3 comprising the amino acid sequence of ARESRVSFEAAMDY;
and (d) HVR-L1 comprising the amino acid sequence of NIATDVA; (e)
HVR-L2 comprising the amino acid sequence of SASF; and (f) HVR-L3
comprising the amino acid sequence of SEPEPYT, or B) (a) a heavy
chain variable domain with the amino acid sequence of SEQ ID NO: 30
as disclosed in US2010/0255010; (b) a light chain variable domain
with the amino acid sequence of SEQ ID NO: 29 as disclosed in
US2010/0255010;
[0087] The term "antibody-dependent cellular cytotoxicity (ADCC)"
refers to lysis of human target cells by an antibody according to
the invention in the presence of effector cells. ADCC is measured
preferably by the treatment of a preparation of HER3 expressing
cells with an antibody according to the invention in the presence
of effector cells such as freshly isolated PBMC or purified
effector cells from buffy coats, like monocytes or natural killer
(NK) cells or a permanently growing NK cell line.
[0088] Cell-mediated effector functions like ADCC of monoclonal
antibodies can be enhanced by engineering their oligosaccharide
component as described in Umana, P., et al., Nature Biotechnol. 17
(1999) 176-180, and U.S. Pat. No. 6,602,684. IgG1 type antibodies,
the most commonly used therapeutic antibodies, are glycoproteins
that have a conserved N-linked glycosylation site at Asn297 in each
CH2 domain. The two complex biantennary oligosaccharides attached
to Asn297 are buried between the CH2 domains, forming extensive
contacts with the polypeptide backbone, and their presence is
essential for the antibody to mediate effector functions such as
antibody dependent cellular cytotoxicity (ADCC) (Lifely, M. R., et
al., Glycobiology 5 (1995) 813-822; Jefferis, R., et al., Immunol.
Rev. 163 (1998) 59-76; Wright, A., and Morrison, S. L., Trends
Biotechnol. 15 (1997) 26-32). Umana, P., et al., Nature Biotechnol.
17 (1999) 176-180 and WO 99/54342 showed that overexpression in
Chinese hamster ovary (CHO) cells of
13(1,4)-N-acetylglucosaminyltransferase III ("GnTIII"), a
glycosyltransferase catalyzing the formation of bisected
oligosaccharides, significantly increases the in vitro ADCC
activity of antibodies. Alterations in the composition of the
Asn297 carbohydrate or its elimination affect also binding to
Fc.gamma.R and C1q (Umana, P., et al., Nature Biotechnol. 17 (1999)
176-180; Davies, J., et al., Biotechnol. Bioeng. 74 (2001) 288-294;
Mimura, Y., et al., J. Biol. Chem. 276 (2001) 45539-45547; Radaev,
S., et al., J. Biol. Chem. 276 (2001) 16478-16483; Shields, R. L.,
et al., J. Biol. Chem. 276 (2001) 6591-6604; Shields, R. L., et
al., J. Biol. Chem. 277 (2002) 26733-26740; Simmons, L. C., et al.,
J. Immunol. Methods 263 (2002) 133-147).
[0089] Methods to enhance cell-mediated effector functions of
monoclonal antibodies via glycoengineering are reported e.g. in WO
2005/044859, WO 2004/065540, WO2007/031875, Umana, P., et al.,
Nature Biotechnol. 17 (1999) 176-180, WO 99/154342, WO 2005/018572,
WO 2006/116260, WO 2006/114700, WO 2004/065540, WO 2005/011735, WO
2005/027966, WO 1997/028267, US 2006/0134709, US 2005/0054048, US
2005/0152894, WO 2003/035835 and WO 2000/061739 or e.g. in Niwa,
R., et al., J. Immunol. Methods 306 (2005) 151-160; Shinkawa, T.,
et al, J Biol Chem, 278 (2003) 3466-3473; WO 03/055993 and US
2005/0249722.
[0090] In one embodiment of the invention, the antibody according
to the invention is afucosylated wich means the antibody is
glycosylated (if it comprises an Fc part of IgG1 or IgG3 subclass)
with a sugar chain at Asn297 whereby the amount of fucose within
said sugar chain is 80% or lower (Numbering according to Kabat),
e.g. between 80% and 1%. In another embodiment is the amount of
fucose within said sugar chain is 65% or lower, in one embodiment
between 5% and 65%, in one embodiment from 0% to 65%, and in one
embodiment the amount of fucose within said sugar chain is 0%. Such
antibodies are referred to in the following as "afucosylated
antibodies" or "non-fucosylated antibodies". Such afucosylated
antibodies show enhanced ADCC whereas other antibody properties
remain substantially unaffected.
[0091] In a further embodiment the amount of N-glycolylneuraminic
acid (NGNA) is 1% or less and/or the amount of N-terminal
alpha-1,3-galactose is 1% or less within said sugar chain. The
sugar chain show preferably the characteristics of N-linked glycans
attached to Asn297 of an antibody recombinantly expressed in a CHO
cell.
[0092] "Asn297" according to the invention means amino acid
asparagine located at about position 297 in the Fc region. Based on
minor sequence variations of antibodies, Asn297 can also be located
some amino acids (usually not more than .+-.3 amino acids) upstream
or downstream of position 297, i.e. between position 294 and
300.
[0093] The term "the sugar chains show characteristics of N-linked
glycans attached to Asn297 of an antibody recombinantly expressed
in a CHO cell" denotes that the sugar chain at Asn297 of the full
length parent antibody according to the invention has the same
structure and sugar residue sequence except for the fucose residue
as those of the same antibody expressed in unmodified CHO cells,
e.g. as those reported in WO 2006/103100.
[0094] The term "NGNA" as used within this application denotes the
sugar residue N-glycolyl-neuraminic acid.
[0095] Glycosylation of human IgG1 or IgG3 occurs at Asn297 as core
fucosylated biantennary complex oligosaccharide glycosylation
terminated with up to two Gal residues. Human constant heavy chain
regions of the IgG1 or IgG3 subclass are reported in detail by
Kabat, E., A., et al., Sequences of Proteins of Immunological
Interest, 5th Ed. Public Health Service, National Institutes of
Health, Bethesda, Md. (1991), and by Brueggemann, M., et al., J.
Exp. Med. 166 (1987) 1351-1361; Love, T. W., et al., Methods
Enzymol. 178 (1989) 515-527. These structures are designated as GO,
G1 (.alpha.-1,6- or .alpha.-1,3-), or G2 glycan residues, depending
from the amount of terminal Gal residues (Raju, T. S., Bioprocess
Int. 1 (2003) 44-53). CHO type glycosylation of antibody Fc parts
is e.g. described by Routier, F. H., Glycoconjugate J. 14 (1997)
201-207. Antibodies which are recombinantly expressed in
non-glycomodified CHO host cells usually are fucosylated at Asn297
in an amount of at least 85%. The modified oligosaccharides of the
full length parent antibody may be hybrid or complex. Preferably
the bisected, reduced/not-fucosylated oligosaccharides are hybrid.
In another embodiment, the bisected, reduced/not-fucosylated
oligosaccharides are complex.
[0096] According to the invention "amount of fucose" means the
amount of said sugar within the sugar chain at Asn297, related to
the sum of all glycostructures attached to Asn297 (e.g. complex,
hybrid and high mannose structures) measured by MALDI-TOF mass
spectrometry (e.g. in LC/MS system) and calculated as average value
(see e.g WO 2008/077546). The relative amount of fucose is the
percentage of fucose-containing structures related to all
glycostructures identified in an N-Glycosidase F treated sample
(e.g. complex, hybrid and oligo- and high-mannose structures,
resp.) by MALDI-TOF.
[0097] The antibodies according to the invention are preferably
produced by recombinant means. Such methods are widely known in the
state of the art and comprise protein expression in prokaryotic and
eukaryotic cells with subsequent isolation of the antibody
polypeptide and usually purification to a pharmaceutically
acceptable purity. For the protein expression nucleic acids
encoding light and heavy chains or fragments thereof are inserted
into expression vectors by standard methods. Expression is
performed in appropriate prokaryotic or eukaryotic host cells, such
as CHO cells, NS0 cells, SP2/0 cells, HEK293 cells, COS cells,
yeast, or E. coli cells, and the antibody is recovered from the
cells (from the supernatant or after cells lysis). Recombinant
production of antibodies is well-known in the state of the art and
described, for example, in the review articles of Makrides, S. C.,
Protein Expr. Purif. 17 (1999) 183-202; Geisse, S., et al., Protein
Expr. Purif. 8 (1996) 271-282; Kaufman, R. J., Mol. Biotechnol. 16
(2000) 151-161; Werner, R. G., Drug Res. 48 (1998) 870-880. The
antibodies may be present in whole cells, in a cell lysate, or in a
partially purified, or substantially pure form. Purification is
performed in order to eliminate other cellular components or other
contaminants, e.g., other cellular nucleic acids or proteins, by
standard techniques, including, column chromatography and others
well known in the art (see Ausubel, F., et al., ed. Current
Protocols in Molecular Biology, Greene Publishing and Wiley
Interscience, New York (1987)). Expression in NS0 cells is
described by, e.g., Barnes, L. M., et al., Cytotechnology 32 (2000)
109-123; Barnes, L. M., et al., Biotech. Bioeng. 73 (2001) 261-270.
Transient expression is described by, e.g., Durocher, Y., et al.,
Nucl. Acids. Res. 30 (2002) E9. Cloning of variable domains is
described by Orlandi, R., et al., Proc. Natl. Acad. Sci. USA 86
(1989) 3833-3837; Carter, P., et al., Proc. Natl. Acad. Sci. USA 89
(1992) 4285-4289; Norderhaug, L., et al., J. Immunol. Methods 204
(1997) 77-87. A preferred transient expression system (HEK 293) is
described by Schlaeger, E.-J. and Christensen, K., in
Cytotechnology 30 (1999) 71-83, and by Schlaeger, E.-J., in J.
Immunol. Methods 194 (1996) 191-199. Monoclonal antibodies are
suitably separated from the culture medium by conventional
immunoglobulin purification procedures such as, for example,
protein A-Sepharose, hydroxylapatite chromatography, gel
electrophoresis, dialysis, or affinity chromatography. DNA and RNA
encoding the monoclonal antibodies is readily isolated and
sequenced using conventional procedures. The hybridoma cells can
serve as a source of such DNA and RNA. Once isolated, the DNA may
be inserted into expression vectors, which are then transfected
into host cells, such as HEK 293 cells, CHO cells, or myeloma cells
that do not otherwise produce immunoglobulin protein, to obtain the
synthesis of recombinant monoclonal antibodies in the host cells.
Antibodies obtainable from said cell lines are preferred
embodiments of the invention. Afocusylated antibodies are
preferably prepared via glycoengineering as descrined above.
[0098] The heavy and light chain variable domains according to the
invention are combined with sequences of promoter, translation
initiation, constant region, 3' untranslated region,
polyadenylation, and transcription termination to form expression
vector constructs. The heavy and light chain expression constructs
can be combined into a single vector, co-transfected, serially
transfected, or separately transfected into host cells which are
then fused to form a single host cell expressing both chains.
[0099] In one aspect of the invention the antibodies of the
combination are administered as a pharmaceutical composition
comprising the respective antibody. In another aspect, the present
invention provides a composition, e.g. a pharmaceutical
composition, containing an antibody according to the present
invention, formulated together with a pharmaceutical carrier.
[0100] As used herein, "pharmaceutical carrier" includes any and
all solvents, dispersion media, coatings, antibacterial and
antifungal agents, isotonic and absorption delaying agents, and the
like that are physiologically compatible. Preferably, the carrier
is suitable for intravenous, intramuscular, subcutaneous,
parenteral, spinal or epidermal administration (e.g. by injection
or infusion).
[0101] A composition of the present invention can be administered
by a variety of methods known in the art. As will be appreciated by
the skilled artisan, the route and/or mode of administration will
vary depending upon the desired results. To administer a compound
of the invention by certain routes of administration, it may be
necessary to coat the compound with, or co-administer the compound
with, a material to prevent its inactivation. For example, the
compound may be administered to a subject in an appropriate
carrier, for example, liposomes, or a diluent. Pharmaceutically
acceptable diluents include saline and aqueous buffer solutions.
Pharmaceutical carriers include sterile aqueous solutions or
dispersions and sterile powders for the extemporaneous preparation
of sterile injectable solutions or dispersion. The use of such
media and agents for pharmaceutically active substances is known in
the art.
[0102] The phrases "parenteral administration" and "administered
parenterally" as used herein means modes of administration other
than enteral and topical administration, usually by injection, and
includes, without limitation, intravenous, intramuscular,
intra-arterial, intrathecal, intracapsular, intraorbital,
intracardiac, intradermal, intraperitoneal, transtracheal,
subcutaneous, subcuticular, intra-articular, subcapsular,
subarachnoid, intraspinal, epidural and intrasternal injection and
infusion.
[0103] The term "cancer" as used herein may be, for example, lung
cancer, non small cell lung (NSCL) cancer, bronchioloalviolar cell
lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of
the head or neck, cutaneous or intraocular melanoma, uterine
cancer, ovarian cancer, rectal cancer, cancer of the anal region,
stomach cancer, gastric cancer, colorectal cancer, breast cancer,
uterine cancer, carcinoma of the fallopian tubes, carcinoma of the
endometrium, carcinoma of the cervix, carcinoma of the vagina,
carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus,
cancer of the small intestine, cancer of the endocrine system,
cancer of the thyroid gland, cancer of the parathyroid gland,
cancer of the adrenal gland, sarcoma of soft tissue, cancer of the
urethra, cancer of the penis, prostate cancer, cancer of the
bladder, cancer of the kidney or ureter, renal cell carcinoma,
carcinoma of the renal pelvis, mesothelioma, hepatocellular cancer,
biliary cancer, neoplasms of the central nervous system (CNS),
spinal axis tumors, brain stem glioma, glioblastoma multiforme,
astrocytomas, schwanomas, ependymonas, medulloblastomas,
meningiomas, squamous cell carcinomas, pituitary adenoma, lymphoma,
lymphocytic leukemia, including refractory versions of any of the
above cancers, or a combination of one or more of the above
cancers.
[0104] Another aspect of the invention is an anti-HER3-antibody
according to the invention for the treatment of cancer in
combination with an antibody which binds to human HER2 and which
inhibits dimerization of HER2, wherein the cancer is a HER2-normal
cancer. Another aspect of the invention is the use of an antibody
which binds to human HER3 for the manufacture of a medicament for
the treatment of cancer in combination with an antibody which binds
to human HER2 and which inhibits dimerization of HER2, wherein the
cancer is a HER2-normal cancer. Another aspect of the invention is
a method of treatment of a patient suffering from cancer by
administering an anti-HER3-antibody antibody according to the
invention to said patient in the need of such treatment in
combination with an antibody which binds to human HER2 and which
inhibits dimerization of HER2, wherein the cancer is a HER2-normal
cancer. In one embodiment, a) the anti-HER3 antibody used in this
combination is characterized in comprising as VH an amino acid
sequence of SEQ ID NO:8 and an as VL an amino acid sequence of SEQ
ID NO: 10, b) the anti-HER2 antibody used in this combination is
pertzumab, and c) the cancer is breast cancer, ovarian cancer,
gastric cancer, prostate cancer, pancreatic cancer or cancer of the
head or neck (or in one embodiment breast cancer).
[0105] Another aspect of the invention is an anti-HER3 antibody
according to the invention for the treatment of cancer in
combination with an antibody which binds to human HER1 wherein
both, the antibody which binds to human HER3 and the antibody which
binds to human HER1, are characterized in being glycosylated with a
sugar chain at Asn297 whereby the amount of fucose within said
sugar chain is 65% or lower. Another aspect of the invention is the
use of an antibody which binds to human HER3 for the manufacture of
a medicament for the treatment of cancer in combination with an
antibody which binds to human HER1 wherein both, the antibody which
binds to human HER3 and the antibody which binds to human HER1, are
characterized in being glycosylated with a sugar chain at Asn297
whereby the amount of fucose within said sugar chain is 65% or
lower. Another aspect of the invention is a method of treatment of
a patient suffering from cancer by administering an anti-HER3
antibody antibody according to the invention to said patient in the
need of such treatment in combination with an antibody which binds
to human HER1 wherein both, the antibody which binds to human HER3
and the antibody which binds to human HER1, are characterized in
being glycosylated with a sugar chain at Asn297 whereby the amount
of fucose within said sugar chain is 65% or lower. In one
embodiment, a) the anti-HER3 antibody used in this combination is
characterized in comprising as VH an amino acid sequence of SEQ ID
NO:8 and an as VL an amino acid sequence of SEQ ID NO: 10, b) the
anti-HER1 antibody used in this combination is characterized in
comprising as VH an amino acid sequence of SEQ ID NO:20 and an as
VL an amino acid sequence of SEQ ID NO: 21, and c) the cancer is
lung cancer, breast cancer, colorectal cancer, or head and neck
cancer.
[0106] In one preferred embodiment of the invention all such cancer
mentioned above are further characterized by HER3 expression. HER3
expression refers to HER3 protein nad/or gene expression
(amplification). The expression level of HER3 may be detected by an
immunohistochemical method, whereas said HER3 gene amplification
status can be measured with in situ hybridization methods, like
fluorescence in situ hybridization techniques (FISH). Corresponding
assays and kits are well known in the art, for protein expression
assays as well as for the detection of gene amplifications.
Alternatively other methods like qRT-PCR might be used to detect
levels of HER3 gene expression. The expression level of HER3 can,
inter alia, be detected by an immunohistochemical method. Such
methods are well known in the art (see e.g. analogous methods and
test for HER2 expression levels below).
[0107] In one preferred embodiment the cancer is characterized by a
high (increased) pHER3/HER3 ratio (analyzed by e.g. by IHC of fresh
frozen tumor tissue; in preclinical setting Western blot Standard
SDS-PAGE and Western blotting was performed using a phosphor-HER3
antibody (.alpha.Phospho-HER3 clone 21D3 [Tyr1289]; Cell Signaling
Technologies, #4791) or anti-HER3 antibody (.alpha.HER3 clone C-17;
Santa Cruz, #sc-285). E.g. Signal can be detected using
electrochemiluminescence (Amersham, RPN2209) and percent inhibition
of HER3 receptor phosphorylation calculated for each concentration
of HER3 antibody is tested. For analysis of HER3 phosphorylation in
tumors, tumor lysates are prepared and equal amounts (20
.mu.g/lane) and are separated on SDS page. Western blottingfor HER3
and phosphorylated HER3 (pHER3) is performed as above)
[0108] In the context of the combination therapy of HER3 antibody
with anti-HER2 antibodies, which anti-HER2 antibodies inhibit HER2
dimerization, the term "HER2-normal cancer" as used herein refers
to a cancer/tumorous tissue etc. which comprises cancer cells which
have normal levels of HER2, meaning they don't have HER2
overexpression, as defined for HER2-positive cancer, or they are
not negative for HER2 expression. For the purpose of the present
invention, "HER2-normal cancer" has an immunohistochemistry (IHC)
score of 2+ and an in situ hybridization (ISH) amplification ratio
<2.0 (i.e. is ISH-negative) or an immunohistochemistry (IHC)
score of 1+ and an in situ hybridization (ISH) amplification ratio
<2.0 (i.e. is ISH-negative). Accordingly, HER2-normal cancer is
present if a low (IHC 1+) or moderate (IHC 2+) HER2 (protein)
expression level detected e.g. by immunohistochemical methods and
no HER2 gene amplification, detected by in-situ-hybridization (ISH
negative, like a HER2 gene copy <4 copies of the HER2 gene per
tumor cell or ratio of <2.0 for the number of HER2 gene copies
to the number of signals for CEP17.), is found in samples obtained
from the patients such as breast tissue biopsies or breast tissue
resections or in tissue derived from metastatic sites. In one
embodiment "HER2-normal cancer" is defined as an
immunohistochemistry (IHC) score of HER2(2+) and ISH negative or
immunohistochemistry (IHC) score of HER2(1+) and ISH negative (IHC
1+/ISH-negative or IHC 2+/ISH-negative).
[0109] The expression level of HER2 may be detected by an
immunohistochemical method, whereas said HER2 gene amplification
status can be measured with in situ hybridization methods, like
fluorescence in situ hybridization techniques (FISH). Corresponding
assays and kits are well known in the art, for protein expression
assays as well as for the detection of gene amplifications.
Alternatively other methods like qRT-PCR might be used to detect
levels of HER2 gene expression.
[0110] The expression level of HER2 can, inter alia, be detected by
an immunohistochemical method. Such methods are well known in the
art and corresponding commercial kits are available. Exemplary kits
which may be used in accordance with the present invention are,
inter alia, HerceptTest.TM. produced and distributed by the company
Dako or the test called Ventana Pathway.TM.. The level of HER2
protein expression may be assessed by using the reagents provided
with and following the protocol of the HercepTest.TM.. A skilled
person will be aware of further means and methods for determining
the expression level of HER2 by immunohistochemical methods; see
for example WO 2005/117553. Therefore, the expression level of HER2
can be easily and reproducibly determined by a person skilled in
the art without undue burden. However, to ensure accurate and
reproducible results, the testing must be performed in a
specialized laboratory, which can ensure validation of the testing
procedures.
[0111] The expression level of HER2 can be classified in a low
expression level, an intermediate expression level and a high
expression level. It is preferred in context of this invention that
HER2-normal disease is defined by a low or weak expression level of
HER2 (e.g. HER2(1+ or 2+) by IHC) and a negative ISH result, for
example determined in a sample of a cancer patient. Therefore
parallel testing using immunohistochemistry and in situ
hybridisation is preferred.
[0112] The recommended scoring system to evaluate the IHC staining
patterns in breast cancer which reflect the expression levels of
HER2 designated herein HER2(0), HER2(+), HER2(++) and HER2(+++), is
as follows:
[0113] The below IHC staining patterns are recommended for
determining HER2 status in breast cancer (see Dako Herceptest
package insert).
TABLE-US-00002 HER2 Staining over- Intensity expression Score
Staining Pattern assessment 0 No staining is observed or membrane
staining negative is observed in <10% of the tumor cells 1+ A
faint/barely perceptible membrane staining is negative detected in
>10% of the tumor cells. The cells are only stained in part of
their membrane. 2+ A weak to moderate complete membrane weakly
staining is detected in >10% of the tumor cells. positive. 3+ A
strong complete membrane staining is strongly detected in >10%
of the tumor cells. positive
[0114] The above IHC staining patterns are routinely used in
determining HER2 status in breast cancer. The terms HER2(+),
HER2(++) and HER2(+++) used herein are equivalent to the terms
HER2(1+), HER2(2+) and HER2(3+). A "normal HER2 protein expression
level" used in context of this invention corresponds to a 1+ score
("negative assessment" according to the table shown herein above),
and a 2+ score "weakly positive". As described herein above in
detail, the evaluation of the protein expression level (i.e. the
scoring system as shown in the table) is based on results obtained
by immunohistochemical methods. As a standard or routinely, the
HER-2 status is, accordingly, performed by immunohistochemistry
with one of two FDA-approved commercial kits available; namely the
Dako Herceptest.TM. and the Ventana Pathway.TM.. These are
semi-quantitative assays which stratify expression levels into 0
(<20,000 receptors per cell, no expression visible by IHC
staining), 1+(.about.100,000 receptors per cell, partial membrane
staining, <10% of cells overexpressing HER-2), 2+(.about.500,000
receptors per cell, light to moderate complete membrane staining,
>10% of cells overexpressing HER-2), and 3+(.about.2,000,000
receptors per cell, strong complete membrane staining, >10% of
cells overexpressing HER-2).
[0115] Alternatively, further methods for the evaluation of the
protein expression level of HER2 may be used, e.g. Western Blots,
ELISA-based detection systems and so on.
[0116] The below IHC staining patterns are recommended for
determining HER2 status in gastric cancer (see Dako Herceptest
package insert):
TABLE-US-00003 Staining HER2 Intensity Surgical specimen - Biopsy
specimen - Overexpression Score staining pattern staining pattern
Assessment 0 No reactivity or no No reactivity or no Negative
membranous reactivity in membranous reactivity in <10% of tumour
cells any tumour cell 1+ Faint/barely perceptible Tumour cell
cluster (.gtoreq.5 Negative membranous reactivity cells) with a
faint/barely in .gtoreq.10% of tumour perceptible membranous cells;
cells are reactive reactivity irrespective of only in part of their
percentage of tumour cells membrane stained 2+ Weak to moderate
Tumour cell cluster (.gtoreq.5 Equivocal complete, basolateral or
cells) with a weak to lateral membranous moderate complete,
reactivity in .gtoreq.10% of basolateral or lateral tumour cells
membranous reactivity irrespective of percentage of tumour cells
stained 3+ Strong complete, Tumour cell cluster (.gtoreq.5 Positive
basolateral or lateral cells) with a strong membranous reactivity
in complete, basolateral or .gtoreq.10% of tumour cells lateral
membranous reactivity irrespective of percentage of tumour cells
stained HER2-normal disease is defined by a low or weak expression
level of HER2 (e.g. HER2(1+ or 2+) by IHC) and a negative ISH
result.
[0117] In accordance with the above, the sample to be assessed can
be (obtained) from a patient with HER2-normal cancer as defined
above. For example, the sample may be obtained from a tumorous
tissue, (a) tumor(s) and, accordingly, is (a) tumor cell(s) or (a)
tumor tissue(s) suspected of being HER2 expressing tumour, like a
breast tumor. A person skilled in the art is in the position to
identify such tumors and/or individuals/patients suffering from
corresponding cancer using standard techniques known in the art and
methods disclosed herein. Generally, said tumor cell or cancer cell
may be obtained from any biological source/organism, particularly
any biological source/organism, suffering from the above-mentioned
cancer. In context of this invention particular useful cells are,
preferably, human cells. These cells can be obtained from e.g.
biopsies or from biological samples. The tumor/cancer/tumor
cell/cancer cell is a solid tumor/cancer/tumor cell/cancer cell. In
accordance with the above, the cancer/tumor cell may be a breast
cancer/tumor cell or said sample comprises a cancer/tumor cell,
such as a breast cancer/tumor cell. In line with the above, said
tumor/cancer may be a breast tumor/cancer.
[0118] In the context of the combination therapy of an anti-HER3
antibody with an anti-HER1 antibody, wherein both (or at least
one), the antibody which binds to human HER3 and the antibody which
binds to human HER1, are characterized in being glycosylated with a
sugar chain at Asn297 whereby the amount of fucose within said
sugar chain is 65% or lower, HER1 expression refers to HER1 protein
and/or gene expression (amplification). The expression level of
HER1 may be detected by an immunohistochemical method, whereas said
HER1 gene amplification status can be measured with in situ
hybridization methods, like fluorescence in situ hybridization
techniques (FISH). Corresponding assays and kits are well known in
the art, for protein expression assays as well as for the detection
of gene amplifications. Alternatively other methods like qRT-PCR
might be used to detect levels of HER1 gene expression. The
expression level of HER1 can, inter alia, be detected by an
immunohistochemical method. Such methods are well known in the art
(see e.g. analogous methods and test for HER2 expression levels
above). Compositions of the antibodies described herein may also
contain adjuvants such as preservatives, wetting agents,
emulsifying agents and dispersing agents. Prevention of presence of
microorganisms may be ensured both by sterilization procedures,
supra, and by the inclusion of various antibacterial and antifungal
agents, for example, paraben, chlorobutanol, phenol, sorbic acid,
and the like. It may also be desirable to include isotonic agents,
such as sugars, sodium chloride, and the like into the
compositions. In addition, prolonged absorption of the injectable
pharmaceutical form may be brought about by the inclusion of agents
which delay absorption such as aluminum monostearate and
gelatin.
[0119] Regardless of the route of administration selected, the
compounds of the present invention, which may be used in a suitable
hydrated form, and/or the pharmaceutical compositions of the
present invention, are formulated into pharmaceutically acceptable
dosage forms by conventional methods known to those of skill in the
art.
[0120] Actual dosage levels of the active ingredients in the
pharmaceutical compositions of the present invention may be varied
so as to obtain an amount of the active ingredient which is
effective to achieve the desired therapeutic response for a
particular patient, composition, and mode of administration,
without being toxic to the patient. The selected dosage level will
depend upon a variety of pharmacokinetic factors including the
activity of the particular compositions of the present invention
employed, the route of administration, the time of administration,
the rate of excretion of the particular compound being employed,
the duration of the treatment, other drugs, compounds and/or
materials used in combination with the particular compositions
employed, the age, sex, weight, condition, general health and prior
medical history of the patient being treated, and like factors well
known in the medical arts.
[0121] The composition must be sterile and fluid to the extent that
the composition is deliverable by syringe. In addition to water,
the carrier preferably is an isotonic buffered saline solution.
[0122] Proper fluidity can be maintained, for example, by use of
coating such as lecithin, by maintenance of required particle size
in the case of dispersion and by use of surfactants. In many cases,
it is preferable to include isotonic agents, for example, sugars,
polyalcohols such as mannitol or sorbitol, and sodium chloride in
the composition.
[0123] The term "treating" as used herein, unless otherwise
indicated, means reversing, alleviating, inhibiting the progress
of, or preventing, either partially or completely, the growth of
tumors, tumor metastases, or other cancer-causing or neoplastic
cells in a patient. The term "treatment" as used herein, unless
otherwise indicated, refers to the act of treating.
[0124] The phrase "a method of treating" or its equivalent, when
applied to, for example, cancer refers to a procedure or course of
action that is designed to reduce or eliminate the number of cancer
cells in a patient, or to alleviate the symptoms of a cancer. "A
method of treating" cancer or another proliferative disorder does
not necessarily mean that the cancer cells or other disorder will,
in fact, be eliminated, that the number of cells or disorder will,
in fact, be reduced, or that the symptoms of a cancer or other
disorder will, in fact, be alleviated. Often, a method of treating
cancer will be performed even with a low likelihood of success, but
which, given the medical history and estimated survival expectancy
of a patient, is nevertheless deemed an overall beneficial course
of action.
[0125] It is self-evident that the antibodies are administered to
the patient in therapeutically effective amount which is the amount
of the subject compound or combination that will elicit the
biological or medical response of a tissue, system, animal or human
that is being sought by the researcher, veterinarian, medical
doctor or other clinician.
[0126] The term "in combination with" refers to the
"co-administration" or "co-administering" of the anti-HER3 antibody
which is administered additionally to the anti-HER2 antibody, (or
anti-HER1 antibody, respectively). The "co-administration" means
that the first antibody is administered additionally to the second
antibody either simultaneously or sequentially. The
coadministration can be simultaneous or sequential in either order,
wherein preferably there is a time period while both (or all)
active agents simultaneously exert their biological activities.
When both antibodies are administered simultaneously the dose is
administered on the same day in one administration, e.g. during one
continuous infusion. When both antibodies are administered
sequentially the dose is administered either on the same day in two
separate administrations, e.g. two separate continuous infusions,
or one of the antibodies is administered on day 1 and the second
antibody is administered on day 2 to day 7, preferably on day 2 to
4. The terms "co-administration" or "co-administering" with respect
to the maintenance doses of the first antibody and the second
antibody mean that the maintenance doses can be either administered
simultaneously, e.g. during one continuous infusion, if the
treatment cycle is appropriate for both antibodies. Or the
maintenance doses are administered sequentially, either within one
or several days, e.g. the maintenance dose of the first antibody is
administered every 3 weeks, and the maintenance dose of the second
is administered every 2 weeks. Also other treatment cycles/usually
from 1 to 4 weeks, preferably from 2 to 3 weeks, may be used for
both antibodies.
[0127] The amount of antibody co-administration and the timing of
administration will depend on the type (species, gender, age,
weight, etc.) and condition of the patient being treated and the
severity of the disease or condition being treated. Usually typical
dosages antibodies are used. For example, the dosages for
administration of the antibodies according to the invention can be
about 1 .mu.g/kg to 50 mg/kg (e.g. 0.1-20 mg/kg) of antibody by one
or more separate administrations, or by continuous infusion. A
typical daily dosage might range from about 1 .mu.g/kg to about 100
mg/kg. In a preferred aspect, the antibodies are administered every
two to three weeks, at a dose ranged from about 1 mg/kg to about 15
mg/kg. A preferred dose for trastuzumab is a loading dose of 4
mg/kg administered as continuous infusion and subsequent 3-weekly
infusions of 2 mg/kg to 6 mg/kg, preferably 2 mg/kg, administered
as continuous infusion until disease progression is detected.
[0128] In the context of this invention, additional other
cytotoxic, chemotherapeutic or anti-cancer agents, or compounds
that enhance the effects of such agents may be used in combination
treatment of the present invention. Such agents include, for
example: alkylating agents or agents with an alkylating action,
such as cyclophosphamide (CTX; e.g. Cytoxan.RTM.), chlorambucil
(CHL; e.g. Leukeran.RTM.), cisplatin (CisP; e.g. Platinol.RTM.)
busulfan (e.g. Myleran.RTM.), melphalan, carmustine (BCNU),
streptozotocin, triethylenemelamine (TEM), mitomycin C, and the
like; anti-metabolites, such as methotrexate (MTX), etoposide
(VP16; e.g. Vepesid.RTM.), 6-mercaptopurine (6MP), 6-thiocguanine
(6TG), cytarabine (Ara-C), 5-fluorouracil (5-FU), capecitabine
(e.g. Xeloda.RTM.), dacarbazine (DTIC), and the like; antibiotics,
such as actinomycin D, doxorubicin (DXR; e.g. Adriamycin.RTM.),
daunorubicin (daunomycin), bleomycin, mithramycin and the like;
alkaloids, such as vinca alkaloids such as vincristine (VCR),
vinblastine, and the like; and other antitumor agents, such as
paclitaxel (e.g. Taxol.RTM.) and paclitaxel derivatives, the
cytostatic agents, glucocorticoids such as dexamethasone (DEX; e.g.
Decadron.RTM.) and corticosteroids such as prednisone, nucleoside
enzyme inhibitors such as hydroxyurea, amino acid depleting enzymes
such as asparaginase, leucovorin and other folic acid derivatives,
and similar, diverse antitumor agents. The following agents may
also be used as additional agents: amifostine (e.g. Ethyol.RTM.),
dactinomycin, mechlorethamine (nitrogen mustard), streptozocin,
cyclophosphamide, lomustine (CCNU), doxorubicin lipo (e.g.
Doxil.RTM.), gemcitabine (e.g. Gemzar.RTM.), daunorubicin lipo
(e.g. Daunoxome.RTM.), procarbazine, mitomycin, docetaxel (e.g.
Taxotere.RTM.), aldesleukin, carboplatin, oxaliplatin, cladribine,
camptothecin, CPT 11 (irinotecan), 10-hydroxy 7-ethyl-camptothecin
(SN38), floxuridine, fludarabine, ifosfamide, idarubicin, mesna,
interferon beta, interferon alpha, mitoxantrone, topotecan,
leuprolide, megestrol, melphalan, mercaptopurine, plicamycin,
mitotane, pegaspargase, pentostatin, pipobroman, plicamycin,
tamoxifen, teniposide, testolactone, thioguanine, thiotepa, uracil
mustard, vinorelbine, chlorambucil. In one embodiment the
combination treatment of the present invention is used without such
additional cytotoxic, chemotherapeutic or anti-cancer agents, or
compounds that enhance the effects of such agents.
[0129] In the context of this invention, an anti-hormonal agent may
be used in combination treatment of the present invention. As used
herein, the term "anti-hormonal agent" includes natural or
synthetic organic or peptidic compounds that act to regulate or
inhibit hormone action on tumors. Antihormonal agents include, for
example: steroid receptor antagonists, anti-estrogens such as
tamoxifen, raloxifene, aromatase inhibiting 4(5)-imidazoles, other
aromatase inhibitors, 42-hydroxytamoxifen, trioxifene, keoxifene,
LY 117018, onapristone, and toremifene (e.g. Fareston.RTM.);
anti-androgens such as flutamide, nilutamide, bicalutamide,
leuprolide, and goserelin; and pharmaceutically acceptable salts,
acids or derivatives of any of the above; agonists and/or
antagonists of glycoprotein hormones such as follicle stimulating
hormone (FSH), thyroid stimulating hormone (TSH), and luteinizing
hormone (LH) and LHRH (leuteinizing hormone-releasing hormone); the
LHRH agonist goserelin acetate, commercially available as
Zoladex.RTM. (AstraZeneca); the LHRH antagonist D-alaninamide
N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridin-
yl)-D-alanyl-L-seryl-N6-(3-pyridinylcarbonyl)-L-lysyl-N6-(3-pyridinyl-carb-
onyl)-D-lysyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-proline (e.g
Antide.RTM., Ares-Serono); the LHRH antagonist ganirelix acetate;
the steroidal anti-androgens cyproterone acetate (CPA) and
megestrol acetate, commercially available as Megace.RTM.
(Bristol-Myers Oncology); the nonsteroidal anti-androgen flutamide
(2-methyl-N-[4, 20-nitro-3-(trifluoromethyl) phenylpropanamide),
commercially available as Eulexin.RTM. (Schering Corp.); the
non-steroidal anti-androgen nilutamide,
(5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl-4'-nitrophenyl)-4,4-dimethyl--
imidazolidine-dione); and antagonists for other non-permissive
receptors, such as antagonists for RAR (retinoic acid receptor),
RXR (retinoid X receptor), TR (thyroid receptor), VDR (vitamin-D
receptor), and the like. In one embodiment the combination
treatment of the present invention is used without such additional
anti-hormonal agent.
[0130] The use of the cytotoxic and other anticancer agents
described above in chemotherapeutic regimens is generally well
characterized in the cancer therapy arts, and their use herein
falls under the same considerations for monitoring tolerance and
effectiveness and for controlling administration routes and
dosages, with some adjustments. For example, the actual dosages of
the cytotoxic agents may vary depending upon the patient's cultured
cell response determined by using histoculture methods. Generally,
the dosage will be reduced compared to the amount used in the
absence of additional other agents.
[0131] Typical dosages of an effective cytotoxic agent can be in
the ranges recommended by the manufacturer, and where indicated by
in vitro responses or responses in animal models, can be reduced by
up to about one order of magnitude concentration or amount. Thus,
the actual dosage will depend upon the judgment of the physician,
the condition of the patient, and the effectiveness of the
therapeutic method based on the in vitro responsiveness of the
primary cultured malignant cells or histocultured tissue sample, or
the responses observed in the appropriate animal models.
[0132] In the context of this invention, additional
antiproliferative agents may be used in the combination treatment
of the present invention, including, for example: Inhibitors of the
enzyme farnesyl protein transferase and inhibitors of the receptor
tyrosine kinase PDGFR, including the compounds disclosed and
claimed in U.S. Pat. Nos. 6,080,769, 6,194,438, 6,258,824,
6,586,447, 6,071,935, 6,495,564, 6,150,377, 6,596,735 and
6,479,513, and International Patent Publication WO 01/40217. In one
embodiment the combination treatment of the present invention is
used without such additional antiproliferative agents.
[0133] In the context of this invention, an effective amount of
ionizing radiation may be carried out and/or a radiopharmaceutical
may be used in addition to combination treatment of the present
invention. The source of radiation can be either external or
internal to the patient being treated. When the source is external
to the patient, the therapy is known as external beam radiation
therapy (EBRT). When the source of radiation is internal to the
patient, the treatment is called brachytherapy (BT). Radioactive
atoms for use in the context of this invention can be selected from
the group including, but not limited to, radium, cesium-137,
iridium-192, americium-241, gold-198, cobalt-57, copper-67,
technetium-99, iodine-123, iodine-131, and indium-111. Where the
EGFR kinase inhibitor according to this invention is an antibody,
it is also possible to label the antibody with such radioactive
isotopes. In one embodiment the combination treatment of the
present invention is used without such additional ionizing
radiation.
[0134] Radiation therapy is a standard treatment for controlling
unresectable or inoperable tumors and/or tumor metastases. Improved
results have been seen when radiation therapy has been combined
with chemotherapy. Radiation therapy is based on the principle that
high-dose radiation delivered to a target area will result in the
death of reproductive cells in both tumor and normal tissues. The
radiation dosage regimen is generally defined in terms of radiation
absorbed dose (Gy), time and fractionation, and must be carefully
defined by the oncologist. The amount of radiation a patient
receives will depend on various considerations, but the two most
important are the location of the tumor in relation to other
critical structures or organs of the body, and the extent to which
the tumor has spread. A typical course of treatment for a patient
undergoing radiation therapy will be a treatment schedule over a 1
to 6 week period, with a total dose of between 10 and 80 Gy
administered to the patient in a single daily fraction of about 1.8
to 2.0 Gy, 5 days a week. In a preferred embodiment of this
invention there is synergy when tumors in human patients are
treated with the combination treatment of the invention and
radiation. In other words, the inhibition of tumor growth by means
of the agents comprising the combination or single therapy of the
invention is enhanced when combined with radiation, optionally with
additional chemotherapeutic or anticancer agents. Parameters of
adjuvant radiation therapies are, for example, contained in
International Patent Publication WO 99/60023.
[0135] The antibodies are administered to a patient according to
known methods, by intravenous administration as a bolus or by
continuous infusion over a period of time, by intramuscular,
intraperitoneal, intracerobrospinal, subcutaneous, intra-articular,
intrasynovial, or intrathecal routes. Intravenous or subcutaneous
administration of the antibodies is preferred.
[0136] The present invention further provides an article of
manufacture comprising a container, a composition within the
container comprising an anti-HER3 antibody and a package insert
instructing the user of the composition to administer said
anti-HER3 antibody to a patient suffering from HER2 normal cancer
in combination with an anti-HER2 antibody which inhibits the
dimerization of HER2.
[0137] The present invention further provides an article of
manufacture comprising a container, a composition within the
container comprising an anti-HER3 antibody and a package insert
instructing the user of the composition to administer said
anti-HER3 antibody to a patient suffering from cancer in
combination with an anti-HER2 antibody which inhibits the
dimerization of HER2.
[0138] The present invention further provides an article of
manufacture comprising a container, a composition within the
container comprising an anti-HER3 antibody and a package insert
instructing the user of the composition to administer said
anti-HER3 antibody to a patient suffering from cancer in
combination with an anti-HER1 antibody wherein both, the antibody
which binds to human HER3 and the antibody which binds to human
HER1, are characterized in being glycosylated with a sugar chain at
Asn297 whereby the amount of fucose within said sugar chain is 65%
or lower.
[0139] The term "package insert" refers to instructions customarily
included in commercial packages of therapeutic products, which may
include information about the indications, usage, dosage,
administration, contraindications and/or warnings concerning the
use of such therapeutic products.
[0140] In one embodiment, the article of manufacture containers may
further include a pharmaceutically acceptable carrier. The article
of manufacture may further include a sterile diluent, which is
preferably stored in a separate additional container.
[0141] In the following one series of embodiments of the invention
is listed: [0142] 1. An antibody which binds to human HER3 for use
in the treatment of cancer in combination with an antibody which
binds to human HER2 and which inhibits dimerization of HER2,
wherein the cancer is a HER2-normal cancer. [0143] 2. The antibody
of embodiment 1, wherein the antibody which binds to human HER3 is
characterized in that the heavy chain variable domain comprises a
CDR3H region of SEQ ID NO: 1, a CDR2H region of SEQ ID NO: 2, and a
CDR1H region of SEQ ID NO:3, and the light chain variable domain
comprises a CDR3L region of SEQ ID NO: 4, a CDR2L region of SEQ ID
NO:5, and a CDR1L region of SEQ ID NO:6 or a CDR1L region of SEQ ID
NO:7. [0144] 3. The antibody of embodiment 1, wherein the antibody
which binds to human HER3 is characterized in that [0145] the heavy
chain variable domain VH is SEQ ID NO:8; and the light chain
variable domain VL is SEQ ID NO:9, or the light chain variable
domain VL is SEQ ID NO:10, or the light chain variable domain VL is
SEQ ID NO:11; or a humanized version thereof. [0146] 4. The
antibody of embodiment 1, wherein the antibody which binds to human
HER3 is characterized in comprising as heavy chain variable domain
a CDR3H region of SEQ ID NO: 1, a CDR2H region of SEQ ID NO: 2, and
a CDR1H region of SEQ ID NO:3, and the light chain variable domain
comprises a CDR3L region of SEQ ID NO: 4, a CDR2L region of SEQ ID
NO:5, and a CDR1L region of SEQ ID NO:6. [0147] 5. The antibody of
embodiment 1, wherein the antibody which bindsto human HER3 is
characterized in that [0148] the heavy chain variable domain VH is
SEQ ID NO:8; and the light chain variable domain VL is SEQ ID NO:9,
or the light chain variable domain VL is SEQ ID NO:11. [0149] 6.
The antibody of embodiment 1, wherein the antibody which binds to
human HER3 is characterized in comprising as heavy chain variable
domain a CDR3H region of SEQ ID NO: 1, a CDR2H region of SEQ ID NO:
2, and a CDR1H region of SEQ ID NO:3, and the light chain variable
domain comprises a CDR3L region of SEQ ID NO: 4, a CDR2L region of
SEQ ID NO:5, and a CDR1L region of SEQ ID NO:7. [0150] 7. The
antibody of embodiment 1, wherein the antibody which binds to human
HER3 is characterized in that [0151] the heavy chain variable
domain VH is SEQ ID NO:8; and the light chain variable domain VL is
SEQ ID NO:10. [0152] 8. The antibody of any one of embodiments 1 to
7, wherein the antibody which binds to human HER3 is characterized
in that is glycosylated with a sugar chain at Asn297 whereby the
amount of fucose within said sugar chain is 65% or lower. [0153] 9.
The antibody of any one of embodiments 1 to 8, wherein the antibody
which binds to human HER2 and which inhibits dimerization of HER2
is pertuzumab. [0154] 10. The antibody of any one of embodiments 1
to 9, wherein the cancer is characterized by a HER3 expression.
[0155] 11. The antibody of any one of embodiments 1 to 10, wherein
the cancer is breast cancer, ovarian cancer, gastric cancer,
prostate cancer, pancreatic cancer or cancer of the head or neck
breast cancer. In the following another series of embodiments of
the invention is listed: [0156] 1. Use of an antibody which binds
to human HER3 for the manufacture of a medicament for the treatment
of cancer in combination with an antibody which binds to human HER2
and which inhibits dimerization of HER2, wherein the cancer is a
HER2-normal cancer. [0157] 2. The use of embodiment 1, wherein the
antibody which binds to human HER3 is characterized in that the
heavy chain variable domain comprises a CDR3H region of SEQ ID NO:
1, a CDR2H region of SEQ ID NO: 2, and a CDR1H region of SEQ ID
NO:3, and the light chain variable domain comprises a CDR3L region
of SEQ ID NO: 4, a CDR2L region of SEQ ID NO:5, and a CDR1L region
of SEQ ID NO:6 or a CDR1L region of SEQ ID NO:7. [0158] 3. The use
of embodiment 1, wherein the antibody which binds to human HER3 is
characterized in that [0159] the heavy chain variable domain VH is
SEQ ID NO:8; and the light chain variable domain VL is SEQ ID NO:9,
or the light chain variable domain VL is SEQ ID NO:10, or the light
chain variable domain VL is SEQ ID NO:11; or a humanized version
thereof. [0160] 4. The use of embodiment 1, wherein the antibody
which binds to human HER3 is characterized in comprising as heavy
chain variable domain a CDR3H region of SEQ ID NO: 1, a CDR2H
region of SEQ ID NO: 2, and a CDR1H region of SEQ ID NO:3, and the
light chain variable domain comprises a CDR3L region of SEQ ID NO:
4, a CDR2L region of SEQ ID NO:5, and a CDR1L region of SEQ ID
NO:6. [0161] 5. The use of embodiment 1, wherein the antibody which
bindsto human HER3 is characterized in that [0162] the heavy chain
variable domain VH is SEQ ID NO:8; and the light chain variable
domain VL is SEQ ID NO:9, or the light chain variable domain VL is
SEQ ID NO:11. [0163] 6. The use of embodiment 1, wherein the
antibody which binds to human HER3 is characterized in comprising
as heavy chain variable domain a CDR3H region of SEQ ID NO: 1, a
CDR2H region of SEQ ID NO: 2, and a CDR1H region of SEQ ID NO:3,
and the light chain variable domain comprises a CDR3L region of SEQ
ID NO: 4, a CDR2L region of SEQ ID NO:5, and a CDR1L region of SEQ
ID NO:7. [0164] 7. The use of embodiment 1, wherein the antibody
which binds to human HER3 is characterized in that [0165] the heavy
chain variable domain VH is SEQ ID NO:8; and the light chain
variable domain VL is SEQ ID NO:10. [0166] 8. The use of any one of
embodiments 1 to 7, wherein the antibody which binds to human HER3
is characterized in that is glycosylated with a sugar chain at
Asn297 whereby the amount of fucose within said sugar chain is 65%
or lower. [0167] 9. The use of any one of embodiments 1 to 8,
wherein the antibody which binds to human HER2 and which inhibits
dimerization of HER2 is pertuzumab. [0168] 10. The use of any one
of embodiments 1 to 9, wherein the cancer is characterized by a
HER3 expression. [0169] 11. The use of any one of embodiments 1 to
10, wherein the cancer is breast cancer, ovarian cancer, gastric
cancer, prostate cancer, pancreatic cancer or cancer of the head or
neck breast cancer. In the following another series of embodiments
of the invention is listed: [0170] 1. A method of treating a
patient suffering from a HER2-normal cancer wherein the method
comprises the co-administration of an antibody which binds to human
HER3 in combination with an antibody which binds to human HER2 and
which inhibits dimerization of HER2. [0171] 2. The method of
embodiment 1, wherein the antibody which binds to human HER3 is
characterized in that the heavy chain variable domain comprises a
CDR3H region of SEQ ID NO: 1, a CDR2H region of SEQ ID NO: 2, and a
CDR1H region of SEQ ID NO:3, and the light chain variable domain
comprises a CDR3L region of SEQ ID NO: 4, a CDR2L region of SEQ ID
NO:5, and a CDR1L region of SEQ ID NO:6 or a CDR1L region of SEQ ID
NO:7. [0172] 3. The method of embodiment 1, wherein the antibody
which binds to human HER3 is characterized in that [0173] the heavy
chain variable domain VH is SEQ ID NO:8; and the light chain
variable domain VL is SEQ ID NO:9, or the light chain variable
domain VL is SEQ ID NO:10, or the light chain variable domain VL is
SEQ ID NO:11; or a humanized version thereof. [0174] 4. The method
of embodiment 1, wherein the antibody which binds to human HER3 is
characterized in comprising as heavy chain variable domain a CDR3H
region of SEQ ID NO: 1, a CDR2H region of SEQ ID NO: 2, and a CDR1H
region of SEQ ID NO:3, and the light chain variable domain
comprises a CDR3L region of SEQ ID NO: 4, a CDR2L region of SEQ ID
NO:5, and a CDR1L region of SEQ ID NO:6. [0175] 5. The method of
embodiment 1, wherein the antibody which bindsto human HER3 is
characterized in that [0176] the heavy chain variable domain VH is
SEQ ID NO:8; and the light chain variable domain VL is SEQ ID NO:9,
or the light chain variable domain VL is SEQ ID NO:11. [0177] 6.
The method of embodiment 1, wherein the antibody which binds to
human HER3 is characterized in comprising as heavy chain variable
domain a CDR3H region of SEQ ID NO: 1, a CDR2H region of SEQ ID NO:
2, and a CDR1H region of SEQ ID NO:3, and the light chain variable
domain comprises a CDR3L region of SEQ ID NO: 4, a CDR2L region of
SEQ ID NO:5, and a CDR1L region of SEQ ID NO:7. [0178] 7. The
method of embodiment 1, wherein the antibody which binds to human
HER3 is characterized in that [0179] the heavy chain variable
domain VH is SEQ ID NO:8; and the light chain variable domain VL is
SEQ ID NO:10. [0180] 8. The method of any one of embodiments 1 to
7, wherein the antibody which binds to human HER3 is characterized
in that is glycosylated with a sugar chain at Asn297 whereby the
amount of fucose within said sugar chain is 65% or lower. [0181] 9.
The method of any one of embodiments 1 to 8, wherein the antibody
which binds to human HER2 and which inhibits dimerization of HER2
is pertuzumab. [0182] 10. The method of any one of embodiments 1 to
9, wherein the cancer is characterized by a HER3 expression. [0183]
11. The method of any one of embodiments 1 to 10, wherein the
cancer is breast cancer, ovarian cancer, gastric cancer, prostate
cancer, pancreatic cancer or cancer of the head or neck breast
cancer. In the following another series of embodiments of the
invention is listed: [0184] 1. An antibody which binds to human
HER3 for use in the treatment of cancer in combination with an
antibody which binds to human HER1, wherein at least one of the
antibody which binds to human HER3 and the antibody which binds to
human HER1 is characterized in that the antibody is glycosylated
with a sugar chain at Asn297 whereby the amount of fucose within
said sugar chain is 65% or lower. [0185] 2. The antibody of
embodiment 1, wherein both, the antibody which binds to human HER3
and the antibody which binds to human HER1, are characterized in
being glycosylated with a sugar chain at Asn297 whereby the amount
of fucose within said sugar chain is 65% or lower. [0186] 3. The
antibody of any one of embodiments 1 to 2, wherein the antibody
which binds to human HER3 is characterized in comprising as heavy
chain variable domain a CDR3H region of SEQ ID NO: 1, a CDR2H
region of SEQ ID NO: 2, and a CDR1H region of SEQ ID NO:3, and the
light chain variable domain comprises a CDR3L region of SEQ ID NO:
4, a CDR2L region of SEQ ID NO:5, and a CDR1L region of SEQ ID
NO:7. [0187] 4. The antibody of any one of embodiments 1 to 2,
wherein the antibody which binds to human HER3 is characterized in
that [0188] the heavy chain variable domain VH is SEQ ID NO:8; and
the light chain variable domain VL is SEQ ID NO:10. [0189] 5. The
antibody of any one of embodiments 3 to 4, wherein the antibody
which binds to human HER1 is characterized in that [0190] the heavy
chain variable domain VH is SEQ ID NO:20; and the light chain
variable domain VL is SEQ ID NO:21. [0191] 6. The antibody of any
one of embodiments 1 to 5, wherein the cancer is characterized by a
HER3 expression. [0192] 7. The antibody of embodiment 6, wherein
the cancer is characterized by a HER1 expression. [0193] 8. The
antibody of any one of embodiments 1 to 8, wherein the cancer is
lung cancer, breast cancer, colorectal cancer, or head and neck
cancer. In the following another series of embodiments of the
invention is listed: [0194] 1. Use of an antibody which binds to
human HER3 for the manufacture of a medicament for the treatment of
cancer in combination with an antibody which binds to human HER1,
wherein at least one of the antibody which binds to human HER3 and
the antibody which binds to human HER1 is characterized in that the
antibody is glycosylated with a sugar chain at Asn297 whereby the
amount of fucose within said sugar chain is 65% or lower. [0195] 2.
The use of embodiment 1, wherein both, the antibody which binds to
human HER3 and the antibody which binds to human HER1, are
characterized in being glycosylated with a sugar chain at Asn297
whereby the amount of fucose within said sugar chain is 65% or
lower. [0196] 3. The use of any one of embodiments 1 to 2, wherein
the antibody which binds to human HER3 is characterized in
comprising as heavy chain variable domain a CDR3H region of SEQ ID
NO: 1, a CDR2H region of SEQ ID NO: 2, and a CDR1H region of SEQ ID
NO:3, and the light chain variable domain comprises a CDR3L region
of SEQ ID NO: 4, a CDR2L region of SEQ ID NO:5, and a CDR1L region
of SEQ ID NO:7. [0197] 4. The use of any one of embodiments 1 to 2,
wherein the antibody which binds to human HER3 is characterized in
that [0198] the heavy chain variable domain VH is SEQ ID NO:8; and
the light chain variable domain VL is SEQ ID NO:10. [0199] 5. The
use of any one of embodiments 3 to 4, wherein the antibody which
binds to human HER1 is characterized in that [0200] the heavy chain
variable domain VH is SEQ ID NO:20; and the light chain variable
domain VL is SEQ ID NO:21. [0201] 6. The use of any one of
embodiments 1 to 5, wherein the cancer is characterized by a HER3
expression. [0202] 7. The use of embodiment 6, wherein the cancer
is characterized by a HER1 expression. [0203] 8. The use of any one
of embodiments 1 to 8, wherein the cancer is lung cancer, breast
cancer, colorectal cancer, or head and neck cancer. In the
following another series of embodiments of the invention is listed:
[0204] 1. A method of treating a patient suffering from a cancer
wherein the method comprises the co-administration an antibody
which binds to human HER3 in combination with an antibody which
binds to human HER1, wherein at least one of the antibody which
binds to human HER3 and the antibody which binds to human HER1 is
characterized in that the antibody is glycosylated with a sugar
chain at Asn297 whereby the amount of fucose within said sugar
chain is 65% or lower. [0205] 2. The method of embodiment 1,
wherein both, the antibody which binds to human HER3 and the
antibody which binds to human HER1, are characterized in being
glycosylated with a sugar chain at Asn297 whereby the amount of
fucose within said sugar chain is 65% or lower. [0206] 3. The
method of any one of embodiments 1 to 2, wherein the antibody which
binds to human HER3 is characterized in comprising as heavy chain
variable domain a CDR3H region of SEQ ID NO: 1, a CDR2H region of
SEQ ID NO: 2, and a CDR1H region of SEQ ID NO:3, and the light
chain variable domain comprises a CDR3L region of SEQ ID NO: 4, a
CDR2L region of SEQ ID NO:5, and a CDR1L region of SEQ ID NO:7.
[0207] 4. The method of any one of embodiments 1 to 2, wherein the
antibody which binds to human HER3 is characterized in that [0208]
the heavy chain variable domain VH is SEQ ID NO:8; and the light
chain variable domain VL is SEQ ID NO:10. [0209] 5. The method of
any one of embodiments 3 to 4, wherein the antibody which binds to
human HER1 is characterized in that
[0210] the heavy chain variable domain VH is SEQ ID NO:20; and the
light chain variable domain VL is SEQ ID NO:21. [0211] 6. The
method of any one of embodiments 1 to 5, wherein the cancer is
characterized by a HER3 expression. [0212] 7. The method of
embodiment 6, wherein the cancer is characterized by a HER1
expression. [0213] 8. The method of any one of embodiments 1 to 8,
wherein the cancer is lung cancer, breast cancer, colorectal
cancer, or head and neck cancer.
[0214] The following examples, sequence listing and figures are
provided to aid the understanding of the present invention, the
true scope of which is set forth in the appended claims. It is
understood that modifications can be made in the procedures set
forth without departing from the spirit of the invention.
DESCRIPTION OF THE SEQUENCE LISTING
TABLE-US-00004 [0215] SEQ ID NO: 1 heavy chain CDR3H, Mab 205.10
SEQ ID NO: 2 heavy chain CDR2H, Mab 205.10 SEQ ID NO: 3 heavy chain
CDR1H, Mab 205.10 SEQ ID NO: 4 light chain CDR3L, Mab 205.10 SEQ ID
NO: 5 light chain CDR2L, Mab 205.10 SEQ ID NO: 6 light chain CDR1L
(variant 1), Mab 205.10 SEQ ID NO: 7 light chain CDR1L (variant 2),
Mab 205.10 SEQ ID NO: 8 heavy chain variable domain VH, Mab 205.10
SEQ ID NO: 9 light chain variable domain VL, Mab 205.10.1 SEQ ID
NO: 10 light chain variable domain VL, Mab 205.10.2 SEQ ID NO: 11
light chain variable domain VL, Mab 205.10.3 SEQ ID NO: 12 human
kappa light chain constant region SEQ ID NO: 13 human heavy chain
constant region derived from IgG1 SEQ ID NO: 14 human heavy chain
constant region derived from IgG1 mutated on L234A and L235A SEQ ID
NO: 15 human heavy chain constant region derived from IgG4 SEQ ID
NO: 16 human heavy chain constant region derived from IgG4 mutated
on S228P SEQ ID NO: 17 human HER3 (including signal peptide) SEQ ID
NO: 18 human HER2 (including signal peptide) SEQ ID NO: 19 human
HER1 (including signal peptide) SEQ ID NO: 20 heavy chain variable
domain VH of anti-HER1 antibody GA201 SEQ ID NO: 21 light chain
variable domain VL of anti-HER1 antibody GA201
EXAMPLES
Example 1
Immunisation
[0216] NMRI mice were immunized with hHER3-ECD (inhouse) and
boosted with hu-HER3-ECD. The immune response was monitored by
testing serum samples against the HER1/2/3-ECD-ELISA. Spleen cells
from mice with sufficient titers of anti-HER3 immunoglobulin were
frozen for later immortalization by fusion with mouse myeloma cell
line P3X63 Ag8.653. One fusion was done and hybridoma supernatants
screened by HER1/2/-ECD-ELISA showing no cross-reacivity, but
binding to HER3-ECD and anti-HER3 selective hybridomas were
selected. The relevant hybridomas were cloned by single cell FACS
sorting. Single cell clones from different hybridomas were cultured
in vitro to produce antibody in tissue culture medium for
characterization. Antibodies were selected by determining their
ability to inhibit HER3 phosphorylation, AKT phosphorylation and
tumor cell proliferation of MDA-MB-175 cells (see Examples below).
From the obtained antibodies, one was further humanized to give the
following antibodies Mab 205.10.1, Mab 205.10.2 and Mab 205.10.3
with their respective VH and VL or CDRs.
TABLE-US-00005 Antibody VH VL Mab 205.10.1 SEQ ID NO: 8 SEQ ID NO:
9 Mab 205.10.2 SEQ ID NO: 8 SEQ ID NO: 10 Mab 205.10.3 SEQ ID NO: 8
SEQ ID NO: 11 Antibody CDR3H CDR2H CDR1H CDR3L CDR2L CDR1L Mab SEQ
ID SEQ ID SEQ ID SEQ ID SEQ ID SEQ ID 205.10.1 NO: 1 NO: 2 NO: 3
NO: 4 NO: 5 NO: 6 Mab SEQ ID SEQ ID SEQ ID SEQ ID SEQ ID SEQ ID
205.10.2 NO: 1 NO: 2 NO: 3 NO: 4 NO: 5 NO: 7 Mab SEQ ID SEQ ID SEQ
ID SEQ ID SEQ ID SEQ ID 205.10.3 NO: 1 NO: 2 NO: 3 NO: 4 NO: 5 NO:
6
[0217] In one embodiment such antibodies were prepared using
constant regions of human origin e.g. SEQ ID NO:12-13.
Example 2
Binding Assays
[0218] a) Antigene Specific ELISA for Binding to Human HER3 ECD
[0219] Soluble human HER3 extracellular domain fused to
Streptavidin Binding Protein (SBP) was captured on a sreptavidine
plate. To define optimal binding of the antibody to SPB-CDCP1,
384-well polystyrene plates (NUNC, streptavidin-coated) delivered
by MicroCoat, Bernried, Germany (ID-No. 1734776-001) have been
coated with pure and stepwise diluted HEK293 supernatant (in
BSA/IMDM buffer:100 mg/ml BSA Fraction V, Roche 10735078001,
dissolved in Iscove's Modified Dulbeccos Medium). Using mouse a
calibration curve of chimeric 205 antibodies the optimal dilution
factor of the HEK293 supernatant in relation to the streptavidin
binding capazity of the microtiter plate was identified. For the
standard coating, SBP-HER3 containing HEK293 supernatant was
diluted (between 1:15 and 1:40) and incubated overnight at 2-80 C
(25 .mu.l per well). Intensive washing of the microtiter plate is
necessary to remove remaining unbound SBP-HER3.
[0220] Antibodies according to the invention antibody were tested
either undiluted or using a 12-step-dilution. 12.5 .mu.l per well
of each sample was incubated for 90 min at room temperature. After
intensive washing using PBS-T (0.1% Tween 20 in PBS) 25 .mu.l goat
anti-human IgG antibodies coupled with HRP (Jackson ImmunoResearch,
Code No: 109-036-098, dilution 1:10000) for human antibodies were
added and incubated for 1 hour. After intensive washing the binding
of the antibodies was detected with ABTS tablets (Roche Diagnostics
GmbH, Cat. No.: 1112422). Absorbance at 405 nm/492 nm was measured
using a standard photometer.
[0221] The table shows the relative binding ratios of the different
antibodies.
TABLE-US-00006 activity hu_HER3- (ratio ECD- IgG- binding to ELISA
ELISA hu_HER3- antibody c(.mu.g/ml) c(.mu.g/ml) ECD/IgG) Mab
205.10.1 583.,1 785.,0 0.74 Mab 205.10.2 396.,4 508.,0 0.,78 Mab
205.10.3 505.4 608.4 0.83
[0222] b) Characterization of the Binding of Anti-HER3 Antibodies
to a Extracellular-Domain-(ECD) Fragment of Human HER3 by Biacore
Analyses:
[0223] For affinity measurements, 30 .mu.g/ml of anti Fc.gamma.
antibodies (from goat, Jackson Immuno Research) were coupled to the
surface of a CM-5 sensor chip by standard amine-coupling and
blocking chemistry on a SPR instrument (Biacore T100). After
conjugation, anti-HER3 antibodies were injected at 25.degree. C. at
a flow rate of 5 .mu.L/min, followed by a dilution series (0 nM to
1000 nM) of human HER3 ECD at 30 .mu.L/min. As running buffer for
the binding experiment PBS/0.1% BSA was used. The chip was then
regenerated with a 60 s pulse of 10 mM glycine-HCl, pH 2.0
solution.
[0224] Calculation of thermodynamic parameters (K.sub.D, binding
constant to HER3) were calculated using a Langmuir 1:1 binding
model.
TABLE-US-00007 Binding Affinity Antibody KD [M] Mab 205.10.1 2.0
.times. 10.sup.-9 Mab 205.10.2 1.1 .times. 10.sup.-9 Mab 205.10.3
2.0 .times. 10.sup.-9
[0225] In a competitive binding assay (Biacore) Mab205.10.1,
Mab205.10.2, and Mab205.10.3 all showed binding to the same
epitope. The anti-HER3-antibodies U1-7, U-53 and U1-59 described in
WO 2007/077028 and Ab#6 described in WO 2008/100624 were
investigated in such assay and revealed to bind to different
epitopes than antibodies Mab205.10.1. Mab205.10.2, and
Mab205.10.3.
Example 3
a) Inhibition of HER3 Phosphorylation in MCF7, FaDu and Mel-Juso
Cells
[0226] Assays were performed in MCF7 and FaDu cells according to
the following protocol: Seed cells with 500,000 cells/well into
Poly-D-Lysine coated 6-well plate in RPMI1640 medium with 10% FCS.
Incubate for 24 h. Remove medium by aspirating, incubate overnight
with 500 .mu.l/well RPMI 1640 with 0.5% FCS. Add antibodies in 500
.mu.l RPMI 1640 with 0.5% FCS. Incubate for 1 h. Add HRG-1b (final
concentration 500 ng/ml) for 10 min. To lyse the cells remove
medium and add 80 .mu.l ice cold Triton-X-100 cell lysis buffer and
incubate for 5 minutes on ice. After transferring the lysate into
1.5 ml reaction tube and centrifugation at 14000 rpm for 15 min at
4.degree. C., transfer supernatant into fresh reaction tubes.
Samples containing equal amounts of protein in SDS loading buffer
were separated on SDS PAGE and blotted by using a semi-dry Western
Blot to nitrocellulose membranes. Membrans were blocked by
1.times.NET-buffer+0.25% gelatine for 1 h hour and pHER3 is
detected by the antibody .alpha.Phospho-HER3/ErbB3 (Tyr1289)(21D3),
Cell Signaling, #4791 and HER3 by the antibody .alpha.ErbB3 (C-17),
Santa Cruz, #sc-285 respectively. After washing and detection of
the signals by an POD coupled secondary antibody, bands were
densometricaly scanned. The anti-HER3 antibodies Mab205.10.1,
Mab205.10.2, and Mab205.10.3 and also anti-HER3 antibodies U1-7,
U-53 and U1-59 described in WO 2007/077028 and Ab#6 described in WO
2008/100624 were investigated. Percent (%) inhibition of anti-HER3
antibodies on receptor phosphorylation in MCF7 cells is shown below
and in FIG. 1A.
TABLE-US-00008 % Inhibition of HER3 phosphorylation in MCF7 cells
pHER3 pHER3 % inhibition % inhibition Antibody [0.1 .mu.g/ml] [1.0
.mu.g/ml] control 0 0 Mab205.10.2 62 96 U1-7 36 44 U1-53 54 51
U1-59 15 70 Ab#6 13 64
[0227] In a further experiment the anti-HER3 antibody Mab205.10.2,
and also the anti-HER3-antibodies 8B8.2D9 described in WO 97/35885,
and 1B4C3 and 2D1D12 described in WO 2003/013602 were investigated.
Percent (%) inhibition of anti-HER3 antibodies on receptor
phosphorylation in MCF7 cells is shown below and in FIG. 1B.
TABLE-US-00009 % Inhibition of HER3 phosphorylation in MCF7 cells
pHER3 pHER3 % inhibition % inhibition Antibody [0.1 .mu.g/ml] [1.0
.mu.g/ml] control 0 0 Mab205.10.2 68 91 8B8.2D9 13 28 1B4C3 49 46
2D1D12 34 34
[0228] Percent (%) inhibition of anti-HER3 antibodies on receptor
phosphorylation in FaDu cells is shown below.
TABLE-US-00010 % Inhibition of HER3 phosphorylation in FaDu cells
pHER3 % pHER3 % pHER3 % Inhibition Inhibition Inhibition Antibody
[0.03 .mu.g/ml] [0.10 .mu.g/ml] [0.30 .mu.g/ml] Control 0 0 0
Mab205.10.2 88 93 97 U1-59 31 25 90
[0229] In a further experiment, the anti-HER3 antibody Mab205.10.2,
and also the anti-HER3-antibodies 8B8.2D9 described in WO 97/35885,
and 1B4C3 and 2D1D12 described in WO 2003/013602, and 105.5 from
(Millipore, Cat. no. 05-47, named .alpha.-HER.sup.ECD in WO
2003/013602) were investigated in Mel-Juso cells. Assays in
Mel-Juso cells were performed according to the aforementioned
protocol for MCF7 and FaDu cells. Cell numbers and media volumes
were adapted to 12-well plates Percent (%) inhibition of anti-HER3
antibodies on receptor phosphorylation in Mel-Juso cells is shown
below and in FIG. 1C.
TABLE-US-00011 % Inhibition of HER3 phosphorylation in Mel-Juso
cells pHER3 pHER3 % inhibition % inhibition Antibody [0.1 .mu.g/ml]
[1.0 .mu.g/ml] control 0 0 Mab205.10.2 75.9 78.8 105.5
(.alpha.-HER.sup.ECD) 22.2 19.5 8B8.2D9 31.3 20.3 1B4C3 20.7 17.5
2D1D12 3.4 39.3
b) AKT Phosphorylation (ELISA)
[0230] Assays were performed in MCF7 cells according to the
following protocol: Seed MCF7 cells with 30000 cells/well into
Poly-D-Lysine coated 96-well plate in RPMI1640 medium with 10% FCS
and incubate for 24 h. Remove medium by tapping on a clean paper
towel, wash carefully with 200 .mu.l serum-free medium, incubate
overnight with 100 .mu.l/well RPMI 1640 with 0.5% FCS. Remove
medium as above; add antibodies in 100 .mu.l RPMI 1640 with 0.5%
FCS and incubate 1.5 h. Add HRG-1b (final concentration 5 ng/ml)
for 10 min. Remove medium as above. To lyse the cells add 100 .mu.l
ice cold cell lysis buffer on ice and resuspend by pipetting
ca.5.times.. Centrifuge plate at 3000 rpm for 10 min at 4.degree.
C. and transfer 80 .mu.l supernatant (or aliquots) into fresh
polypropylene plate and shock-freeze in LN2. Store at -80.degree.
C. until assay.
[0231] AKT1,2(phospho-Ser473) EIA Kit Assay Designs #900-162:
Samples (1:10 diluted) are added to the plate coated with a mouse
MAB specific for the N-terminus of AKT. Incubation 1 h at RT with
shaking. Wash 5.times., incubation with biotinylated
anti-phospho-AKT (Ser473) 1 h at RT with shaking. Wash 5.times.,
incubation with streptavidin-HRP conjugate 30 min at RT with
shaking. Wash 5.times., incubate with TMB substrate 30 min at RT
with shaking. Stop and read at 450 nm.
[0232] Mab 205.10.2 showed an IC50 of the AKT phosphorylation
inhibition of 0.06 .mu.g/ml.
[0233] In an pAKT ELISA in Mel-Juso cell performed as described for
MCF7 cells Mab 205.10.2 showed an IC50 of AKT phosporylation
inhibition of 0.28 .mu.g/ml all the other analyses antibodies show
an IC50 above (>) 50.
TABLE-US-00012 % AKT phosporylation inhibition in Mel-Juso cells
Antibody IC50 [.mu.g/ml] Mab 205.10.2 0.28 105.5
(.alpha.-HER.sup.ECD) 0.81 1B4C3 >50 2D1D12 >50 8B8D9
>50
c) Inhibition of Tumor Cell Proliferation
[0234] The anti-tumor efficacy of HER3 antibodies Mab205.10.1,
Mab205.10.2, and Mab205.10.3 in a cell proliferation assay, using
MDA-MB-175 cells (VII Human Breast Carcinoma Cells, ATCC catalog
no. HTB-25), was assessed. 20,000 cells per well were seeded into
sterile 96 well tissue culture plates with DMEM/F12 cell culture
medium, containing 10% FCS and incubated at 37.degree.
C..+-.1.degree. C. with 5%.+-.1% CO.sub.2 for one day. The cells
are slow growing cells with a doubling time of ca. 1.5 days.
Anti-HER3 antibodies were added in dilution series and further
incubated for 6 days. Cell viability was then assessed using the
alamarBlue.RTM. readout. If the cell viability was reduced to more
than 50% of control, IC50 values were calculated using means of
triplicates for each antibody concentration; otherwise, if the %
inhibition of cell viability at the highest concentration was below
50%, no IC50 could be calculated and it is indicated that IC.sub.50
[.mu.g/ml] is above (>) the highest concentration. Also the
anti-HER3-antibodies U1-59 described in WO 2007/077028 and Ab#6
described in WO 2008/100624 were investigated.
TABLE-US-00013 antibody IC.sub.50 [.mu.g/ml] Mab205.10.1 8.0
Mab205.10.2 3.8 Mab205.10.3 6.8 U1-59 12.4 Ab#6 >60 .mu.g/ml
[0235] In a further experiment the anti-HER3 antibodies 8B8.2D9
described in WO 97/35885, and 1B4C3 described in WO 2003/013602
were investigated.
TABLE-US-00014 antibody IC.sub.50 [.mu.g/ml] 8B8.2D9 >100
.mu.g/ml (29% inhibition at 100 .mu.g/ml) 1B4C3 >100 .mu.g/ml
(26% inhibition at 100 .mu.g/ml)
Example 5
In Vitro ADCC in KPL-4 Tumor Cells by 1 .mu.g/Ml specLysis %
[0236] The target cells KPL4 (ADCC), breast carcinoma, cultivation
in RPMI1640+2 mM L-alanyl-L-Glutamine+10% FCS) were collected with
trypsin/EDTA (Gibco #25300-054) in exponential growth phase. After
a washing step and checking cell number and viability, the aliquot
needed was labeled for 30 min at 37.degree. C. in the cell
incubator with calcein (Invitrogen #C3100MP; 1 vial was resuspended
in 50 .mu.l DMSO for 5 Mio cells in 5 ml medium). Afterwards, the
cells were washed three times with AIM-V medium, the cell number
and viability was checked and the cell number adjusted to 0.3
Mio/ml.
[0237] Meanwhile, PBMC (Peripheral Blood Mononuclear Cells) as
effector cells were prepared by density gradient centrifugation
(Histopaque-1077, Sigma # H8889) according to the manufacturer's
protocol (washing steps 1.times. at 400 g and 2.times. at 350 g 10
min each). The cell number and viability was checked and the cell
number adjusted to 15 Mio/ml.
[0238] 100 .mu.l calcein-stained target cells were plated in
round-bottom 96-well plates, 50 .mu.l diluted, afucosylated
antibody (Mab205.10.1, Mab205.10.2, Mab205.10.3, preparation see
below) which was added and 50 .mu.l effector cells. In some
experiments the target cells were mixed with Redimune.RTM. NF
Liquid (ZLB Behring) at a concentration of 10 mg/ml Redimune.
[0239] As controls served the spontaneous lysis, determined by
co-culturing target and effector cells without antibody and the
maximal lysis, determined by 1% Triton X-100 lysis of target cells
only. The plate was incubated for 4 hours at 37.degree. C. in a
humidified cell incubator.
[0240] The killing of target cells was assessed by measuring LDH
(Lactate Dehydrogenase) release from damaged cells using the
Cytotoxicity Detection kit (LDH Detection Kit, Roche #1 644 793)
according to the manufacturer's instruction. Briefly, 100 .mu.l
supernatant from each well was mixed with 100 .mu.l substrate from
the kit in a transparent flat bottom 96 well plate. The Vmax values
of the substrate's colour reaction was determined in an ELISA
reader at 490 nm for at least 10 min. Percentage of specific
antibody-mediated killing was calculated as follows:
((A-SR)/(MR-SR).times.100, where A is the mean of Vmax at a
specific antibody concentration, SR is the mean of Vmax of the
spontaneous release and MR is the mean of Vmax of the maximal
release.
[0241] As additional readout the calcein retention of intact target
cells was assessed by lysing the remaining target cells in borate
buffer (5 mM sodium borate+0.1% Triton) and measuring the calcein
fluorescence in a fluorescence plate reader. Mab205.10.1,
Mab205.10.2, Mab205.10.3 showed and ADCC [KPL-4] by 1 .mu.g/ml of
specific Lysis of about 40-60%.
[0242] The afucosylated antibody (Mab205.10.1, Mab205.10.2,
Mab205.10.3) were prepared by co-transfection with four plasmids,
two for antibody expression, one for a fusion GnTIII polypeptide
expression (a GnT-III expression vector), and one for mannosidase
II expression (a Golgi mannosidase II expression vector) at a ratio
of 4:4:1:1, respectively in HEK293 or CHO cells.
[0243] The full antibody heavy and light chain DNA sequences were
subcloned into mammalian expression vectors (one for the light
chain and one for the heavy chain) under the control of the MPSV
promoter and upstream of a synthetic polyA site, each vector
carrying an EBV OriP sequence. Antibodies were produced by
co-transfecting HEK293-EBNA cells or CHO cells with the antibody
heavy and light chain expression vectors using a calcium
phosphate-transfection approach. Exponentially growing HEK293-EBNA
cells were transfected by the calcium phosphate method. For the
production of the glycoengineered antibody, the cells were
co-transfected with four plasmids, two for antibody expression, one
for a fusion GnTIII polypeptide expression (a GnT-III expression
vector), and one for mannosidase II expression (a Golgi mannosidase
II expression vector) at a ratio of 4:4:1:1, respectively. Cells
were grown as adherent monolayer cultures in T flasks using DMEM
culture medium supplemented with 10% FCS, and were transfected when
they were between 50 and 80% confluent. For the transfection of a
T150 flask, 15 million cells were seeded 24 hours before
transfection in 25 ml DMEM culture medium supplemented with FCS (at
10% V/V final), and cells were placed at 37.degree. C. in an
incubator with a 5% CO2 atmosphere overnight. For every antibody to
be produced, a solution of DNA, CaCl2 and water was prepared by
mixing 188 .mu.g total plasmid vector DNA (four plasmids, two for
antibody expression (one light chain and one heavy chain), one for
a fusion GnTIII polypeptide expression (a GnT-III expression
vector), and one for mannosidase II expression (a Golgi mannosidase
II expression vector) at a ratio of 4:4:1:1, respectively), water
to a final volume of 938 .mu.l and 938 .mu.l of a 1M CaCl2
solution. To this solution, 1876 .mu.l of a 50 mM HEPES, 280 mM
NaCl, 1.5 mM Na2HPO4 solution at pH 7.05 were added, mixed
immediately for 10 sec and left to stand at room temperature for 20
sec. The suspension was diluted with 46 ml of DMEM supplemented
with 2% FCS, and divided into two T150 flasks in place of the
existing medium.
[0244] The cells were incubated at 37.degree. C., 5% CO2 for about
17 to 20 hours, then medium was replaced with 25 ml DMEM, 10% FCS.
The conditioned culture medium was harvested 7 days
post-transfection by centrifugation for 15 min at 210.times.g, the
solution was sterile filtered (0.22 .mu.m filter) and sodium azide
in a final concentration of 0.01% w/v was added, and kept at
4.degree. C.
[0245] The secreted afucosylated antibodies were purified and the
oligosaccharides attached to the Fc region of the antibodies were
analysed e.g. by MALDI/TOF-MS (as described in e.g. WO
2008/077546). For this analysis oligosaccharides were enzymatically
released from the antibodies by PNGaseF digestion, with the
antibodies being either immobilized on a PVDF membrane or in
solution. The resulting digest solution containing the released
oligosaccharides either prepared directly for MALDI/TOF-MS analysis
or was further digested with EndoH glycosidase prior to sample
preparation for MALDI/TOF-MS analysis. The analyzed amount of
fucose within the sugar chain at Asn297 was between 50-20%.
Example 6
In Vivo Antitumor Efficacy of Anti-HER3 Monotherapy
[0246] The in vivo antitumor efficacy of the antibodies
Mab205.10.1, Mab205.10.2, Mab205.10.3 could be detected in cell and
fragment based models of various tumor origin (e.g. lung cancer,
SCCHN, breast- and pancreatic cancer) transplanted on SCID beige or
nude mice. As examples data are shown for the SCCHN xenograft model
FaDu (cell line based), breast cancer model MAXF449
(fragment-based) and NSCLC model 7177 (fragment-based).
[0247] Test Agents
[0248] Afucosylated Mab205.10.2 (designated Mab 205 in FIGS. 2, 3,
4) was provided as stock solution from Roche, Penzberg, Germany.
Antibody buffer included histidine. Antibody solution was diluted
appropriately in buffer from stock prior injections.
[0249] Cell Lines and Culture Conditions
[0250] FaDu human HNSCC cells were originally obtained from ATCC.
The tumor cell line was routinely cultured in MEM Eagle medium
supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 1 mM
sodium pyruvate and 0.1 mM NEAA at 37.degree. C. in a
water-saturated atmosphere at 5% CO.sub.2. Culture passage was
performed with trypsin/EDTA 1.times. splitting every third day.
[0251] Tumor Fragments
[0252] Tumor fragments were originally taken from patients and
transplanted s.c. to nude donor mice. Subsequently tumor fragments
are serial passaged in vivo. For a preclinical study small tumor
fragments were generated from donor mice and placed s.c. on further
nude mice (MAXF449, 7177).
[0253] Animals
[0254] Female SCID beige or nude mice were purchased from breeder
(e.g. Charles River, Sulzfeld, Germany) and maintained under
specific-pathogen-free condition with daily cycles of 12 h light/12
h darkness according to committed guidelines (GV-Solas; Felasa;
TierschG). Experimental study protocol was reviewed and approved by
local government. After arrival animals were maintained in the
quarantine part of the animal facility for one week to get
accustomed to new environment and for observation. Continuous
health monitoring was carried out on regular basis. Diet food
(Provimi Kliba 3337) and water (acidified pH 2.5-3) were provided
ad libitum.
[0255] Monitoring
[0256] Animals were controlled daily for clinical symptoms and
detection of adverse effects. For monitoring throughout the
experiment body weight of animals was documented.
[0257] Treatment of Animals
[0258] Animal treatment started after animal randomisation after
cell or fragment transplantation when median tumor size was about
100-150 mm.sup.3. Antibody was administered as single agent at 10
or 25 mg/kg i.p. q7d once weekly for 3-6 weeks depending of the
model. The corresponding vehicle was administered on the same
days.
[0259] Antibody Efficacy
[0260] A) FaDu HNSCC Xenograft
[0261] FaDu HNSCC (head and neck squamous cell cancer) xenograft
bearing mice were treated with antibody Mab205.10.2 from study day
14 to 35. As a result, treatment with the Mab205.10.2 antibody
showed significant anti-tumor efficacy with tumors stasis of s.c.
FaDu xenografts. The Tumor Growth Inhibition (TGI) was calculated
at 98%.
[0262] Treatment with Mab 205 (10 mg/kg q7dx3, i.p.) resulted in
tumor stasis of FaDu HNSCCHN transplanted xenografts (see FIG.
2).
[0263] B) MAXF449 Breast Cancer Xenograft
[0264] MAXF449 breast cancer xenograft bearing mice were treated
with antibody Mab205.10.2 from study day 64 to 91. As a result,
treatment with the Mab205.10.2 antibody showed significant
anti-tumor efficacy with tumors stasis of MAXF449 xenografts. The
Tumor Growth Inhibition (TGI) was over 100%.
[0265] Treatment with Mab 205 (10 mg/kg q7d, i.p.) resulted in
tumor stasis of MAXF449 breast cancer transplanted xenografts (see
FIG. 3).
[0266] C) 7177 NSCLC Xenograft
[0267] 7177 NSCLC xenograft bearing mice were treated with antibody
Mab205.10.2 from study day 28 to 56. As a result, treatment with
the Mab205.10.2 antibody showed significant anti-tumor efficacy
with tumors stasis of 7177 NSCLC xenografts. The Tumor Growth
Inhibition (TGI) was over 100%.
[0268] Treatment with Mab 205 (25 mg/kg q7d, i.p.) resulted in
tumor stasis of 7177 NSCLC transplanted xenografts (see FIG.
4).
Example 7
In Vivo Antitumor Efficacy of Anti-HER3 Therapy in Combination with
Pertuzumab
[0269] The human breast cancer cell line ZR-75-1, which is a HER2
normal cancer cell line and expresses HER3, was subcutaneously
(s.c.) inoculated into the right flank of female Balb/c nude mice
(5.times.10.sup.6 cells per animal). Animals were systemically
supplemented with 17.beta.-estradiol pellets and the antibiotic
cefocein (20 mg/kg) was administered s.c. in once-weekly intervals
throughout the whole study period.
[0270] On day 40 after tumor cell inoculation, animals were
randomized and allocated to 3 treatment groups and one vehicle
group, resulting in a median tumor volume of .about.100 mm.sup.3 in
all groups. On the day of randomization, treatment was started in
once-weekly intervals by intra-peritoneal administration of
Mab205.10.2 (10 mg/kg), pertuzumab (30 mg/kg loading dose followed
by a 15 mg/kg maintenance dose), a combination of Mab205.10.2 plus
pertuzumab. Animals were sacrificed on day 81, which was 41 days
after start of treatment and 6 days after the last (6.sup.th)
medication.
[0271] Primary tumor volume (TV) was calculated according to the
NCI protocol (TV=(length.times.width.sup.2)/2), where "length" and
"width" are long and short diameters of tumor mass in mm (Corbett
et al., 1997). Calculation was executed from staging (day 40 after
tumor inoculation) until study termination (day 81 after tumor
inoculation).
[0272] For calculation of percentage tumor growth inhibition (TGI)
during the treatment period, every treated group was compared with
its respective vehicle control. TV.sub.day z represents the tumor
volume of an individual animal at a defined study day (day z) and
TV.sub.day x represents the tumor volume of an individual animal at
the staging day (day x).
[0273] The following formula was applied:
TGI [ % ] = 100 - median ( TV ( treated ) day z - TV ( treated )
day x ) median ( TV ( resp . control ) day z - TV ( resp . control
) day x ) .times. 100 ##EQU00001##
[0274] Results/Efficacy of Treatment on Tumor Volume, Day 81
TABLE-US-00015 Compound TGI (%) anti-HER2 Pertuzumab i.p. 32.9
anti-HER3 Mab205.10.2 i.p. 27.6 anti-HER3 Mab205.10.2 i.p. + 53.2
anti-HER2 Pertuzumab i.p.
Example 8
In Vivo Antitumor Efficacy of Anti-HER3 (Mab205.10.2=RG7116)
Therapy in Combination with Pertuzumab
[0275] Subcutaneous xenograft models were generated by using either
human tumor cell lines (BxPC3, QG56, A549, NCI-H322M, NCI-H1975,
HCC827, HCC827GR, NCI-H441, FaDu) or by implantation of human tumor
tissue fragments. Cell lines and fragments were selected based on a
high pHER3/HER3 ratio (analyzed by Western blot). All experiments
were conducted according to the guidelines of the German Animal
Welfare Act (Tierschutzgesetz).
[0276] For cell line-based xenograft models, cells (5-10.times.106
cells) were injected subcutaneously (s.c.) into female SCID/beige
(BxPC3, QG56, A549, NCI-H322M, NCI-H441, FaDu) or Balb/c nude mice
(HCC827, HCC827GR, NCI-H1975) (both Charles River, Germany). Mice
(n=10 per group) were randomized on Day 21-24 (depending on the
model) stratified for primary tumor size with treatment beginning
thereafter. Mab205.10.2 (abbreviated in this example as RG7116)
treatments (dose 10-25 mg/kg) (n=2-5 doses) were given once weekly
intraperitoneally (i.p.). Saline was used as vehicle control. Tumor
volume was measured by caliper once weekly
(1/2(length.times.(width)2)) and the percentage tumor growth
inhibition (TGI) compared with control animals was calculated as
described in the Supplemental Material.
[0277] Subcutaneous patient-derived tumor xenografts models (PDX)
were evaluated at Oncontest GmbH (Freiburg, Germany) or
Experimental Pharmacology & Oncology Berlin-Buch GmbH (Berlin,
Germany) by transplantation of small human tumor fragments onto
NMRI nude mice. Mice were randomized (n=10 per group) and therapy
performed similar to cell based models.
[0278] An orthotopic cell line-based xenograft mouse model was used
to assess the contribution of ADCC. Therefore, HER3 recombinant
A549-B34 transfectant cells were injected i.v. (3.times.106 cells)
into female SCID-beige mice (Taconics). Mice were randomized on Day
23 (n=15 per group) when evidence of tumor growth in the lung was
confirmed in scout animals. Mice received 10-13 weekly i.p.
injections of 25 mg/kg RG7116 or non-glycoengineered RG7116 or
saline control. The termination criterion was sickness with
locomotion impairment. Median survival was defined as the
experimental day when at least 50% of animals in the group were
sacrificed. Survival data were represented using Kaplan-Meier
curves and differences in median survival between each treatment
group were compared by means of the Pairwise Log-Rank test.
[0279] RG7116 Treatment Results in Strong TGI of Mouse Xenograft
Tumors
[0280] The in vivo activity of RG7116 was investigated using
subcutaneous mouse xenograft models representing different tumor
entities (pancreas, TNBC, SSCHN and NSCLC). All models expressed
HER3 which is significantly phosphorylated, indicating that HER3 is
activated in these models; therefore cell growth could be dependent
on HER3 signaling. Since subcutaneous xenograft models lack immune
effector cells at the site of the tumor, these models reflect only
anti-tumor efficacy mediated via HER3 signaling inhibition; there
is no contribution from ADCC.
[0281] RG7116 demonstrated dose-dependent TGI in a BxPC3 mouse
xenograft model (FIG. 6A). Intraperitoneal doses of RG7116 in the
range 0.3 to 25 mg/kg were highly efficacious and resulted in TGI
of >90% compared with control mice. Only at a dose of 0.1 mg/kg
was partial TGI achieved. At the end of the study (Day 56) mice
were sacrificed and explanted tumor tissue examined for the
presence of HER3 and pHER3. Levels of pHER3 were markedly reduced
in mice treated with single-agent RG7116 at doses of 0.3-25 mg/kg
compared control animals (FIG. 4B). Only the non-efficacious dose
(0.1 mg/kg) of RG7116 failed to inhibit HER3 phosphorylation
completely. When explanted tissue was examined by
immunohistochemistry, the efficacious doses of RG7116 appeared to
down-modulate levels of membrane HER3 compared with tumor explants
treated with vehicle control and 0.1 mg/kg RG7116 (FIG. 4C), with
the same kinetics as seen with Western blotting.
[0282] In HER3-positive human NSCLC (adenocarcinoma and squamous)
models (cell line and fragment based), single-agent RG7116 induced
potent TGI (FIG. 7). Treatment with 4-6 cycles of weekly RG7116 at
doses of 10-25 mg/kg resulted in strong TGI in 5/6 squamous NSCLC
models, including tumor stasis or complete remission in 3/6 (FIG.
7A). FIG. 5B shows an example squamous NSCLC model (LXFE722) in
which complete remission was achieved. In the LXFE646 model, where
single-agent RG7116 did not inhibit tumor growth, tumor stasis was
achieved when RG7116 was combined with a HER1 targeted therapy
(data not shown). Substantial TGI (>50%) was also observed in
5/10 adenocarcinoma NSCLC xenograft models (FIG. 7A).
[0283] c-Met expression status and KRAS mutation status were known
for all of the NSCLC tumor models. The efficacy of RG7116 mediated
by HER3 signal inhibition was low in the three adenocarcinoma cell
lines that overexpressed c-Met (HCC827, Lu7397 and NCI-H441),
whereas TGI of >50% was seen in two KRAS-mutant models (A549 and
LXFA983). No TGI was seen in the third KRAS-mutant cell line
(NCI-H441) which also overexpressed c-Met.
[0284] Furthermore, the efficacy of RG7116 was enhanced when
combined with antibodies targeting HER1 (RG7160 [GA201]; FIG. 7C)
or HER2 (pertuzumab; FIG. 7D) in models in which HER1 (FaDu cells,
expresses HER1) or HER2 (MAXF449 cells, HER2-normal cancer cells)
is the preferred heterodimerisation partner respectively. In both
instances, combination treatment led to long lasting and complete
tumor regression.
[0285] Although the foregoing invention has been described in some
detail by way of illustration and example for purposes of clarity
of understanding, the descriptions and examples should not be
construed as limiting the scope of the invention. The disclosures
of all patent and scientific literature cited herein are expressly
incorporated in their entirety by reference.
Sequence CWU 1
1
21111PRTArtificialheavy chain CDR3H, Mab 205.10 1His Arg Asp Tyr
Tyr Ser Asn Ser Leu Thr Tyr 1 5 10 217PRTArtificialheavy chain
CDR2H, Mab 205.10 2Trp Ile Tyr Ala Gly Thr Gly Ser Pro Ser Tyr Asn
Gln Lys Leu Gln 1 5 10 15 Gly 35PRTArtificialheavy chain CDR1H, Mab
205.10 3Ser Ser Tyr Ile Ser 1 5 49PRTArtificiallight chain CDR3L,
Mab 205.10 4Gln Ser Asp Tyr Ser Tyr Pro Tyr Thr 1 5
57PRTArtificiallight chain CDR2L, Mab 205.10 5Trp Ala Ser Thr Arg
Glu Ser 1 5 617PRTArtificiallight chain CDR1L (variant 1), Mab
205.10 6Lys Ser Ser Gln Ser Leu Leu Asn Ser Gly Asn Gln Lys Asn Tyr
Leu 1 5 10 15 Thr 717PRTArtificiallight chain CDR1L (variant 2),
Mab 205.10 7Lys Ser Ser Gln Ser Val Leu Asn Ser Gly Asn Gln Lys Asn
Tyr Leu 1 5 10 15 Thr 8120PRTArtificialheavy chain variable domain
VH, Mab 205.10 8Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr
Thr Phe Arg Ser Ser 20 25 30 Tyr Ile Ser Trp Val Arg Gln Ala Pro
Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Tyr Ala Gly Thr
Gly Ser Pro Ser Tyr Asn Gln Lys Leu 50 55 60 Gln Gly Arg Val Thr
Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu
Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala
Arg His Arg Asp Tyr Tyr Ser Asn Ser Leu Thr Tyr Trp Gly Gln 100 105
110 Gly Thr Leu Val Thr Val Ser Ser 115 120 9113PRTArtificiallight
chain variable domain VL, Mab 205.10.1 9Asp Ile Val Met Thr Gln Ser
Pro Asp Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Glu Arg Ala Thr Ile
Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser 20 25 30 Gly Asn Gln
Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Pro
Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55
60 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80 Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys
Gln Ser 85 90 95 Asp Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr
Lys Leu Glu Ile 100 105 110 Lys 10113PRTArtificiallight chain
variable domain VL, Mab 205.10.2 10Asp Ile Val Met Thr Gln Ser Pro
Asp Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Glu Arg Ala Thr Ile Asn
Cys Lys Ser Ser Gln Ser Val Leu Asn Ser 20 25 30 Gly Asn Gln Lys
Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Pro Pro
Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65
70 75 80 Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys
Gln Ser 85 90 95 Asp Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr
Lys Leu Glu Ile 100 105 110 Lys 11113PRTArtificiallight chain
variable domain VL, Mab 205.10.3 11Asp Ile Val Met Thr Gln Ser Pro
Asp Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Glu Arg Ala Thr Ile Asn
Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser 20 25 30 Gly Asn Gln Lys
Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Pro Pro
Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65
70 75 80 Ile Ser Ser Leu Gln Ala Glu Asp Val Ser Ile Tyr Tyr Cys
Gln Ser 85 90 95 Asp Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr
Lys Leu Glu Ile 100 105 110 Lys 12107PRTHomo sapiens 12Arg Thr Val
Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 1 5 10 15 Gln
Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 20 25
30 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
35 40 45 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys
Asp Ser 50 55 60 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys
Ala Asp Tyr Glu 65 70 75 80 Lys His Lys Val Tyr Ala Cys Glu Val Thr
His Gln Gly Leu Ser Ser 85 90 95 Pro Val Thr Lys Ser Phe Asn Arg
Gly Glu Cys 100 105 13330PRTHomo sapiens 13Ala Ser Thr Lys Gly Pro
Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly
Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro
Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50
55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln
Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys
Val Asp Lys 85 90 95 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His
Thr Cys Pro Pro Cys 100 105 110 Pro Ala Pro Glu Leu Leu Gly Gly Pro
Ser Val Phe Leu Phe Pro Pro 115 120 125 Lys Pro Lys Asp Thr Leu Met
Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135 140 Val Val Val Asp Val
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 145 150 155 160 Tyr Val
Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170 175
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 180
185 190 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser
Asn 195 200 205 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
Ala Lys Gly 210 215 220 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
Pro Ser Arg Asp Glu 225 230 235 240 Leu Thr Lys Asn Gln Val Ser Leu
Thr Cys Leu Val Lys Gly Phe Tyr 245 250 255 Pro Ser Asp Ile Ala Val
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270 Asn Tyr Lys Thr
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285 Leu Tyr
Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295 300
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 305
310 315 320 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 325 330
14330PRTArtificialhuman heavy chain constant region derived from
IgG1 mutated on L234A and L235A 14Ala Ser Thr Lys Gly Pro Ser Val
Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr
Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro
Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val
His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65
70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val
Asp Lys 85 90 95 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr
Cys Pro Pro Cys 100 105 110 Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser
Val Phe Leu Phe Pro Pro 115 120 125 Lys Pro Lys Asp Thr Leu Met Ile
Ser Arg Thr Pro Glu Val Thr Cys 130 135 140 Val Val Val Asp Val Ser
His Glu Asp Pro Glu Val Lys Phe Asn Trp 145 150 155 160 Tyr Val Asp
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170 175 Glu
Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 180 185
190 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
Lys Gly 210 215 220 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
Ser Arg Asp Glu 225 230 235 240 Leu Thr Lys Asn Gln Val Ser Leu Thr
Cys Leu Val Lys Gly Phe Tyr 245 250 255 Pro Ser Asp Ile Ala Val Glu
Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270 Asn Tyr Lys Thr Thr
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285 Leu Tyr Ser
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295 300 Val
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 305 310
315 320 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 325 330
15327PRTHomo sapiens 15Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
Ala Pro Cys Ser Arg 1 5 10 15 Ser Thr Ser Glu Ser Thr Ala Ala Leu
Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val
Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr 65 70 75 80 Tyr
Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90
95 Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro
100 105 110 Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
Pro Lys 115 120 125 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr
Cys Val Val Val 130 135 140 Asp Val Ser Gln Glu Asp Pro Glu Val Gln
Phe Asn Trp Tyr Val Asp 145 150 155 160 Gly Val Glu Val His Asn Ala
Lys Thr Lys Pro Arg Glu Glu Gln Phe 165 170 175 Asn Ser Thr Tyr Arg
Val Val Ser Val Leu Thr Val Leu His Gln Asp 180 185 190 Trp Leu Asn
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu 195 200 205 Pro
Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 210 215
220 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys
225 230 235 240 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
Pro Ser Asp 245 250 255 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
Glu Asn Asn Tyr Lys 260 265 270 Thr Thr Pro Pro Val Leu Asp Ser Asp
Gly Ser Phe Phe Leu Tyr Ser 275 280 285 Arg Leu Thr Val Asp Lys Ser
Arg Trp Gln Glu Gly Asn Val Phe Ser 290 295 300 Cys Ser Val Met His
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 305 310 315 320 Leu Ser
Leu Ser Leu Gly Lys 325 16327PRTArtificialhuman heavy chain
constant region derived from IgG4 mutated onS228P 16Ala Ser Thr Lys
Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg 1 5 10 15 Ser Thr
Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35
40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr
Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly
Thr Lys Thr 65 70 75 80 Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn
Thr Lys Val Asp Lys 85 90 95 Arg Val Glu Ser Lys Tyr Gly Pro Pro
Cys Pro Pro Cys Pro Ala Pro 100 105 110 Glu Phe Leu Gly Gly Pro Ser
Val Phe Leu Phe Pro Pro Lys Pro Lys 115 120 125 Asp Thr Leu Met Ile
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 130 135 140 Asp Val Ser
Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp 145 150 155 160
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe 165
170 175 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
Asp 180 185 190 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
Lys Gly Leu 195 200 205 Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala
Lys Gly Gln Pro Arg 210 215 220 Glu Pro Gln Val Tyr Thr Leu Pro Pro
Ser Gln Glu Glu Met Thr Lys 225 230 235 240 Asn Gln Val Ser Leu Thr
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 245 250 255 Ile Ala Val Glu
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 260 265 270 Thr Thr
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 275 280 285
Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser 290
295 300 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
Ser 305 310 315 320 Leu Ser Leu Ser Leu Gly Lys 325 171342PRThomo
sapiens 17Met Arg Ala Asn Asp Ala Leu Gln Val Leu Gly Leu Leu Phe
Ser Leu 1 5 10 15 Ala Arg Gly Ser Glu Val Gly Asn Ser Gln Ala Val
Cys Pro Gly Thr 20 25 30 Leu Asn Gly Leu Ser Val Thr Gly Asp Ala
Glu Asn Gln Tyr Gln Thr 35 40 45 Leu Tyr Lys Leu Tyr Glu Arg Cys
Glu Val Val Met Gly Asn Leu Glu 50 55 60 Ile Val Leu Thr Gly His
Asn Ala Asp Leu Ser Phe Leu Gln Trp Ile 65 70 75 80 Arg Glu Val Thr
Gly Tyr Val Leu Val Ala Met Asn Glu Phe Ser Thr 85 90 95 Leu Pro
Leu Pro Asn Leu Arg Val Val Arg Gly Thr Gln Val Tyr Asp 100 105 110
Gly Lys Phe Ala Ile Phe Val Met Leu Asn Tyr Asn Thr Asn Ser Ser 115
120 125 His Ala Leu Arg Gln Leu Arg Leu Thr Gln Leu Thr Glu Ile Leu
Ser 130 135 140 Gly Gly Val Tyr Ile Glu Lys Asn Asp Lys Leu Cys His
Met Asp Thr 145 150 155 160 Ile Asp Trp Arg Asp Ile Val Arg Asp Arg
Asp Ala Glu Ile Val Val 165 170 175 Lys Asp Asn Gly Arg Ser Cys Pro
Pro Cys His Glu Val Cys Lys Gly 180 185 190 Arg Cys Trp Gly Pro Gly
Ser Glu Asp Cys Gln Thr Leu Thr Lys Thr 195 200 205 Ile Cys Ala Pro
Gln Cys Asn Gly His Cys Phe Gly Pro Asn Pro Asn 210 215
220 Gln Cys Cys His Asp Glu Cys Ala Gly Gly Cys Ser Gly Pro Gln Asp
225 230 235 240 Thr Asp Cys Phe Ala Cys Arg His Phe Asn Asp Ser Gly
Ala Cys Val 245 250 255 Pro Arg Cys Pro Gln Pro Leu Val Tyr Asn Lys
Leu Thr Phe Gln Leu 260 265 270 Glu Pro Asn Pro His Thr Lys Tyr Gln
Tyr Gly Gly Val Cys Val Ala 275 280 285 Ser Cys Pro His Asn Phe Val
Val Asp Gln Thr Ser Cys Val Arg Ala 290 295 300 Cys Pro Pro Asp Lys
Met Glu Val Asp Lys Asn Gly Leu Lys Met Cys 305 310 315 320 Glu Pro
Cys Gly Gly Leu Cys Pro Lys Ala Cys Glu Gly Thr Gly Ser 325 330 335
Gly Ser Arg Phe Gln Thr Val Asp Ser Ser Asn Ile Asp Gly Phe Val 340
345 350 Asn Cys Thr Lys Ile Leu Gly Asn Leu Asp Phe Leu Ile Thr Gly
Leu 355 360 365 Asn Gly Asp Pro Trp His Lys Ile Pro Ala Leu Asp Pro
Glu Lys Leu 370 375 380 Asn Val Phe Arg Thr Val Arg Glu Ile Thr Gly
Tyr Leu Asn Ile Gln 385 390 395 400 Ser Trp Pro Pro His Met His Asn
Phe Ser Val Phe Ser Asn Leu Thr 405 410 415 Thr Ile Gly Gly Arg Ser
Leu Tyr Asn Arg Gly Phe Ser Leu Leu Ile 420 425 430 Met Lys Asn Leu
Asn Val Thr Ser Leu Gly Phe Arg Ser Leu Lys Glu 435 440 445 Ile Ser
Ala Gly Arg Ile Tyr Ile Ser Ala Asn Arg Gln Leu Cys Tyr 450 455 460
His His Ser Leu Asn Trp Thr Lys Val Leu Arg Gly Pro Thr Glu Glu 465
470 475 480 Arg Leu Asp Ile Lys His Asn Arg Pro Arg Arg Asp Cys Val
Ala Glu 485 490 495 Gly Lys Val Cys Asp Pro Leu Cys Ser Ser Gly Gly
Cys Trp Gly Pro 500 505 510 Gly Pro Gly Gln Cys Leu Ser Cys Arg Asn
Tyr Ser Arg Gly Gly Val 515 520 525 Cys Val Thr His Cys Asn Phe Leu
Asn Gly Glu Pro Arg Glu Phe Ala 530 535 540 His Glu Ala Glu Cys Phe
Ser Cys His Pro Glu Cys Gln Pro Met Glu 545 550 555 560 Gly Thr Ala
Thr Cys Asn Gly Ser Gly Ser Asp Thr Cys Ala Gln Cys 565 570 575 Ala
His Phe Arg Asp Gly Pro His Cys Val Ser Ser Cys Pro His Gly 580 585
590 Val Leu Gly Ala Lys Gly Pro Ile Tyr Lys Tyr Pro Asp Val Gln Asn
595 600 605 Glu Cys Arg Pro Cys His Glu Asn Cys Thr Gln Gly Cys Lys
Gly Pro 610 615 620 Glu Leu Gln Asp Cys Leu Gly Gln Thr Leu Val Leu
Ile Gly Lys Thr 625 630 635 640 His Leu Thr Met Ala Leu Thr Val Ile
Ala Gly Leu Val Val Ile Phe 645 650 655 Met Met Leu Gly Gly Thr Phe
Leu Tyr Trp Arg Gly Arg Arg Ile Gln 660 665 670 Asn Lys Arg Ala Met
Arg Arg Tyr Leu Glu Arg Gly Glu Ser Ile Glu 675 680 685 Pro Leu Asp
Pro Ser Glu Lys Ala Asn Lys Val Leu Ala Arg Ile Phe 690 695 700 Lys
Glu Thr Glu Leu Arg Lys Leu Lys Val Leu Gly Ser Gly Val Phe 705 710
715 720 Gly Thr Val His Lys Gly Val Trp Ile Pro Glu Gly Glu Ser Ile
Lys 725 730 735 Ile Pro Val Cys Ile Lys Val Ile Glu Asp Lys Ser Gly
Arg Gln Ser 740 745 750 Phe Gln Ala Val Thr Asp His Met Leu Ala Ile
Gly Ser Leu Asp His 755 760 765 Ala His Ile Val Arg Leu Leu Gly Leu
Cys Pro Gly Ser Ser Leu Gln 770 775 780 Leu Val Thr Gln Tyr Leu Pro
Leu Gly Ser Leu Leu Asp His Val Arg 785 790 795 800 Gln His Arg Gly
Ala Leu Gly Pro Gln Leu Leu Leu Asn Trp Gly Val 805 810 815 Gln Ile
Ala Lys Gly Met Tyr Tyr Leu Glu Glu His Gly Met Val His 820 825 830
Arg Asn Leu Ala Ala Arg Asn Val Leu Leu Lys Ser Pro Ser Gln Val 835
840 845 Gln Val Ala Asp Phe Gly Val Ala Asp Leu Leu Pro Pro Asp Asp
Lys 850 855 860 Gln Leu Leu Tyr Ser Glu Ala Lys Thr Pro Ile Lys Trp
Met Ala Leu 865 870 875 880 Glu Ser Ile His Phe Gly Lys Tyr Thr His
Gln Ser Asp Val Trp Ser 885 890 895 Tyr Gly Val Thr Val Trp Glu Leu
Met Thr Phe Gly Ala Glu Pro Tyr 900 905 910 Ala Gly Leu Arg Leu Ala
Glu Val Pro Asp Leu Leu Glu Lys Gly Glu 915 920 925 Arg Leu Ala Gln
Pro Gln Ile Cys Thr Ile Asp Val Tyr Met Val Met 930 935 940 Val Lys
Cys Trp Met Ile Asp Glu Asn Ile Arg Pro Thr Phe Lys Glu 945 950 955
960 Leu Ala Asn Glu Phe Thr Arg Met Ala Arg Asp Pro Pro Arg Tyr Leu
965 970 975 Val Ile Lys Arg Glu Ser Gly Pro Gly Ile Ala Pro Gly Pro
Glu Pro 980 985 990 His Gly Leu Thr Asn Lys Lys Leu Glu Glu Val Glu
Leu Glu Pro Glu 995 1000 1005 Leu Asp Leu Asp Leu Asp Leu Glu Ala
Glu Glu Asp Asn Leu Ala 1010 1015 1020 Thr Thr Thr Leu Gly Ser Ala
Leu Ser Leu Pro Val Gly Thr Leu 1025 1030 1035 Asn Arg Pro Arg Gly
Ser Gln Ser Leu Leu Ser Pro Ser Ser Gly 1040 1045 1050 Tyr Met Pro
Met Asn Gln Gly Asn Leu Gly Glu Ser Cys Gln Glu 1055 1060 1065 Ser
Ala Val Ser Gly Ser Ser Glu Arg Cys Pro Arg Pro Val Ser 1070 1075
1080 Leu His Pro Met Pro Arg Gly Cys Leu Ala Ser Glu Ser Ser Glu
1085 1090 1095 Gly His Val Thr Gly Ser Glu Ala Glu Leu Gln Glu Lys
Val Ser 1100 1105 1110 Met Cys Arg Ser Arg Ser Arg Ser Arg Ser Pro
Arg Pro Arg Gly 1115 1120 1125 Asp Ser Ala Tyr His Ser Gln Arg His
Ser Leu Leu Thr Pro Val 1130 1135 1140 Thr Pro Leu Ser Pro Pro Gly
Leu Glu Glu Glu Asp Val Asn Gly 1145 1150 1155 Tyr Val Met Pro Asp
Thr His Leu Lys Gly Thr Pro Ser Ser Arg 1160 1165 1170 Glu Gly Thr
Leu Ser Ser Val Gly Leu Ser Ser Val Leu Gly Thr 1175 1180 1185 Glu
Glu Glu Asp Glu Asp Glu Glu Tyr Glu Tyr Met Asn Arg Arg 1190 1195
1200 Arg Arg His Ser Pro Pro His Pro Pro Arg Pro Ser Ser Leu Glu
1205 1210 1215 Glu Leu Gly Tyr Glu Tyr Met Asp Val Gly Ser Asp Leu
Ser Ala 1220 1225 1230 Ser Leu Gly Ser Thr Gln Ser Cys Pro Leu His
Pro Val Pro Ile 1235 1240 1245 Met Pro Thr Ala Gly Thr Thr Pro Asp
Glu Asp Tyr Glu Tyr Met 1250 1255 1260 Asn Arg Gln Arg Asp Gly Gly
Gly Pro Gly Gly Asp Tyr Ala Ala 1265 1270 1275 Met Gly Ala Cys Pro
Ala Ser Glu Gln Gly Tyr Glu Glu Met Arg 1280 1285 1290 Ala Phe Gln
Gly Pro Gly His Gln Ala Pro His Val His Tyr Ala 1295 1300 1305 Arg
Leu Lys Thr Leu Arg Ser Leu Glu Ala Thr Asp Ser Ala Phe 1310 1315
1320 Asp Asn Pro Asp Tyr Trp His Ser Arg Leu Phe Pro Lys Ala Asn
1325 1330 1335 Ala Gln Arg Thr 1340 181255PRThomo sapiens 18Met Glu
Leu Ala Ala Leu Cys Arg Trp Gly Leu Leu Leu Ala Leu Leu 1 5 10 15
Pro Pro Gly Ala Ala Ser Thr Gln Val Cys Thr Gly Thr Asp Met Lys 20
25 30 Leu Arg Leu Pro Ala Ser Pro Glu Thr His Leu Asp Met Leu Arg
His 35 40 45 Leu Tyr Gln Gly Cys Gln Val Val Gln Gly Asn Leu Glu
Leu Thr Tyr 50 55 60 Leu Pro Thr Asn Ala Ser Leu Ser Phe Leu Gln
Asp Ile Gln Glu Val 65 70 75 80 Gln Gly Tyr Val Leu Ile Ala His Asn
Gln Val Arg Gln Val Pro Leu 85 90 95 Gln Arg Leu Arg Ile Val Arg
Gly Thr Gln Leu Phe Glu Asp Asn Tyr 100 105 110 Ala Leu Ala Val Leu
Asp Asn Gly Asp Pro Leu Asn Asn Thr Thr Pro 115 120 125 Val Thr Gly
Ala Ser Pro Gly Gly Leu Arg Glu Leu Gln Leu Arg Ser 130 135 140 Leu
Thr Glu Ile Leu Lys Gly Gly Val Leu Ile Gln Arg Asn Pro Gln 145 150
155 160 Leu Cys Tyr Gln Asp Thr Ile Leu Trp Lys Asp Ile Phe His Lys
Asn 165 170 175 Asn Gln Leu Ala Leu Thr Leu Ile Asp Thr Asn Arg Ser
Arg Ala Cys 180 185 190 His Pro Cys Ser Pro Met Cys Lys Gly Ser Arg
Cys Trp Gly Glu Ser 195 200 205 Ser Glu Asp Cys Gln Ser Leu Thr Arg
Thr Val Cys Ala Gly Gly Cys 210 215 220 Ala Arg Cys Lys Gly Pro Leu
Pro Thr Asp Cys Cys His Glu Gln Cys 225 230 235 240 Ala Ala Gly Cys
Thr Gly Pro Lys His Ser Asp Cys Leu Ala Cys Leu 245 250 255 His Phe
Asn His Ser Gly Ile Cys Glu Leu His Cys Pro Ala Leu Val 260 265 270
Thr Tyr Asn Thr Asp Thr Phe Glu Ser Met Pro Asn Pro Glu Gly Arg 275
280 285 Tyr Thr Phe Gly Ala Ser Cys Val Thr Ala Cys Pro Tyr Asn Tyr
Leu 290 295 300 Ser Thr Asp Val Gly Ser Cys Thr Leu Val Cys Pro Leu
His Asn Gln 305 310 315 320 Glu Val Thr Ala Glu Asp Gly Thr Gln Arg
Cys Glu Lys Cys Ser Lys 325 330 335 Pro Cys Ala Arg Val Cys Tyr Gly
Leu Gly Met Glu His Leu Arg Glu 340 345 350 Val Arg Ala Val Thr Ser
Ala Asn Ile Gln Glu Phe Ala Gly Cys Lys 355 360 365 Lys Ile Phe Gly
Ser Leu Ala Phe Leu Pro Glu Ser Phe Asp Gly Asp 370 375 380 Pro Ala
Ser Asn Thr Ala Pro Leu Gln Pro Glu Gln Leu Gln Val Phe 385 390 395
400 Glu Thr Leu Glu Glu Ile Thr Gly Tyr Leu Tyr Ile Ser Ala Trp Pro
405 410 415 Asp Ser Leu Pro Asp Leu Ser Val Phe Gln Asn Leu Gln Val
Ile Arg 420 425 430 Gly Arg Ile Leu His Asn Gly Ala Tyr Ser Leu Thr
Leu Gln Gly Leu 435 440 445 Gly Ile Ser Trp Leu Gly Leu Arg Ser Leu
Arg Glu Leu Gly Ser Gly 450 455 460 Leu Ala Leu Ile His His Asn Thr
His Leu Cys Phe Val His Thr Val 465 470 475 480 Pro Trp Asp Gln Leu
Phe Arg Asn Pro His Gln Ala Leu Leu His Thr 485 490 495 Ala Asn Arg
Pro Glu Asp Glu Cys Val Gly Glu Gly Leu Ala Cys His 500 505 510 Gln
Leu Cys Ala Arg Gly His Cys Trp Gly Pro Gly Pro Thr Gln Cys 515 520
525 Val Asn Cys Ser Gln Phe Leu Arg Gly Gln Glu Cys Val Glu Glu Cys
530 535 540 Arg Val Leu Gln Gly Leu Pro Arg Glu Tyr Val Asn Ala Arg
His Cys 545 550 555 560 Leu Pro Cys His Pro Glu Cys Gln Pro Gln Asn
Gly Ser Val Thr Cys 565 570 575 Phe Gly Pro Glu Ala Asp Gln Cys Val
Ala Cys Ala His Tyr Lys Asp 580 585 590 Pro Pro Phe Cys Val Ala Arg
Cys Pro Ser Gly Val Lys Pro Asp Leu 595 600 605 Ser Tyr Met Pro Ile
Trp Lys Phe Pro Asp Glu Glu Gly Ala Cys Gln 610 615 620 Pro Cys Pro
Ile Asn Cys Thr His Ser Cys Val Asp Leu Asp Asp Lys 625 630 635 640
Gly Cys Pro Ala Glu Gln Arg Ala Ser Pro Leu Thr Ser Ile Ile Ser 645
650 655 Ala Val Val Gly Ile Leu Leu Val Val Val Leu Gly Val Val Phe
Gly 660 665 670 Ile Leu Ile Lys Arg Arg Gln Gln Lys Ile Arg Lys Tyr
Thr Met Arg 675 680 685 Arg Leu Leu Gln Glu Thr Glu Leu Val Glu Pro
Leu Thr Pro Ser Gly 690 695 700 Ala Met Pro Asn Gln Ala Gln Met Arg
Ile Leu Lys Glu Thr Glu Leu 705 710 715 720 Arg Lys Val Lys Val Leu
Gly Ser Gly Ala Phe Gly Thr Val Tyr Lys 725 730 735 Gly Ile Trp Ile
Pro Asp Gly Glu Asn Val Lys Ile Pro Val Ala Ile 740 745 750 Lys Val
Leu Arg Glu Asn Thr Ser Pro Lys Ala Asn Lys Glu Ile Leu 755 760 765
Asp Glu Ala Tyr Val Met Ala Gly Val Gly Ser Pro Tyr Val Ser Arg 770
775 780 Leu Leu Gly Ile Cys Leu Thr Ser Thr Val Gln Leu Val Thr Gln
Leu 785 790 795 800 Met Pro Tyr Gly Cys Leu Leu Asp His Val Arg Glu
Asn Arg Gly Arg 805 810 815 Leu Gly Ser Gln Asp Leu Leu Asn Trp Cys
Met Gln Ile Ala Lys Gly 820 825 830 Met Ser Tyr Leu Glu Asp Val Arg
Leu Val His Arg Asp Leu Ala Ala 835 840 845 Arg Asn Val Leu Val Lys
Ser Pro Asn His Val Lys Ile Thr Asp Phe 850 855 860 Gly Leu Ala Arg
Leu Leu Asp Ile Asp Glu Thr Glu Tyr His Ala Asp 865 870 875 880 Gly
Gly Lys Val Pro Ile Lys Trp Met Ala Leu Glu Ser Ile Leu Arg 885 890
895 Arg Arg Phe Thr His Gln Ser Asp Val Trp Ser Tyr Gly Val Thr Val
900 905 910 Trp Glu Leu Met Thr Phe Gly Ala Lys Pro Tyr Asp Gly Ile
Pro Ala 915 920 925 Arg Glu Ile Pro Asp Leu Leu Glu Lys Gly Glu Arg
Leu Pro Gln Pro 930 935 940 Pro Ile Cys Thr Ile Asp Val Tyr Met Ile
Met Val Lys Cys Trp Met 945 950 955 960 Ile Asp Ser Glu Cys Arg Pro
Arg Phe Arg Glu Leu Val Ser Glu Phe 965 970 975 Ser Arg Met Ala Arg
Asp Pro Gln Arg Phe Val Val Ile Gln Asn Glu 980 985 990 Asp Leu Gly
Pro Ala Ser Pro Leu Asp Ser Thr Phe Tyr Arg Ser Leu 995 1000 1005
Leu Glu Asp Asp Asp Met Gly Asp Leu Val Asp Ala Glu Glu Tyr 1010
1015 1020 Leu Val Pro Gln Gln Gly Phe Phe Cys Pro Asp Pro Ala Pro
Gly 1025 1030 1035 Ala Gly Gly Met Val His His Arg His Arg Ser Ser
Ser Thr Arg 1040 1045 1050 Ser Gly Gly Gly Asp Leu Thr Leu Gly Leu
Glu Pro Ser Glu Glu 1055 1060 1065 Glu Ala Pro Arg Ser Pro Leu Ala
Pro Ser Glu Gly Ala Gly Ser 1070 1075 1080 Asp Val Phe Asp Gly Asp
Leu Gly Met Gly Ala Ala Lys Gly Leu 1085 1090 1095 Gln Ser Leu Pro
Thr His Asp Pro Ser Pro Leu Gln Arg Tyr Ser 1100 1105 1110 Glu Asp
Pro Thr Val Pro Leu Pro Ser Glu Thr Asp Gly Tyr Val 1115 1120 1125
Ala Pro Leu Thr Cys Ser Pro Gln Pro Glu Tyr Val Asn Gln Pro 1130
1135 1140 Asp Val Arg Pro Gln Pro Pro Ser Pro Arg Glu Gly Pro Leu
Pro 1145 1150 1155
Ala Ala Arg Pro Ala Gly Ala Thr Leu Glu Arg Pro Lys Thr Leu 1160
1165 1170 Ser Pro Gly Lys Asn Gly Val Val Lys Asp Val Phe Ala Phe
Gly 1175 1180 1185 Gly Ala Val Glu Asn Pro Glu Tyr Leu Thr Pro Gln
Gly Gly Ala 1190 1195 1200 Ala Pro Gln Pro His Pro Pro Pro Ala Phe
Ser Pro Ala Phe Asp 1205 1210 1215 Asn Leu Tyr Tyr Trp Asp Gln Asp
Pro Pro Glu Arg Gly Ala Pro 1220 1225 1230 Pro Ser Thr Phe Lys Gly
Thr Pro Thr Ala Glu Asn Pro Glu Tyr 1235 1240 1245 Leu Gly Leu Asp
Val Pro Val 1250 1255 191210PRThomo sapiens 19Met Arg Pro Ser Gly
Thr Ala Gly Ala Ala Leu Leu Ala Leu Leu Ala 1 5 10 15 Ala Leu Cys
Pro Ala Ser Arg Ala Leu Glu Glu Lys Lys Val Cys Gln 20 25 30 Gly
Thr Ser Asn Lys Leu Thr Gln Leu Gly Thr Phe Glu Asp His Phe 35 40
45 Leu Ser Leu Gln Arg Met Phe Asn Asn Cys Glu Val Val Leu Gly Asn
50 55 60 Leu Glu Ile Thr Tyr Val Gln Arg Asn Tyr Asp Leu Ser Phe
Leu Lys 65 70 75 80 Thr Ile Gln Glu Val Ala Gly Tyr Val Leu Ile Ala
Leu Asn Thr Val 85 90 95 Glu Arg Ile Pro Leu Glu Asn Leu Gln Ile
Ile Arg Gly Asn Met Tyr 100 105 110 Tyr Glu Asn Ser Tyr Ala Leu Ala
Val Leu Ser Asn Tyr Asp Ala Asn 115 120 125 Lys Thr Gly Leu Lys Glu
Leu Pro Met Arg Asn Leu Gln Glu Ile Leu 130 135 140 His Gly Ala Val
Arg Phe Ser Asn Asn Pro Ala Leu Cys Asn Val Glu 145 150 155 160 Ser
Ile Gln Trp Arg Asp Ile Val Ser Ser Asp Phe Leu Ser Asn Met 165 170
175 Ser Met Asp Phe Gln Asn His Leu Gly Ser Cys Gln Lys Cys Asp Pro
180 185 190 Ser Cys Pro Asn Gly Ser Cys Trp Gly Ala Gly Glu Glu Asn
Cys Gln 195 200 205 Lys Leu Thr Lys Ile Ile Cys Ala Gln Gln Cys Ser
Gly Arg Cys Arg 210 215 220 Gly Lys Ser Pro Ser Asp Cys Cys His Asn
Gln Cys Ala Ala Gly Cys 225 230 235 240 Thr Gly Pro Arg Glu Ser Asp
Cys Leu Val Cys Arg Lys Phe Arg Asp 245 250 255 Glu Ala Thr Cys Lys
Asp Thr Cys Pro Pro Leu Met Leu Tyr Asn Pro 260 265 270 Thr Thr Tyr
Gln Met Asp Val Asn Pro Glu Gly Lys Tyr Ser Phe Gly 275 280 285 Ala
Thr Cys Val Lys Lys Cys Pro Arg Asn Tyr Val Val Thr Asp His 290 295
300 Gly Ser Cys Val Arg Ala Cys Gly Ala Asp Ser Tyr Glu Met Glu Glu
305 310 315 320 Asp Gly Val Arg Lys Cys Lys Lys Cys Glu Gly Pro Cys
Arg Lys Val 325 330 335 Cys Asn Gly Ile Gly Ile Gly Glu Phe Lys Asp
Ser Leu Ser Ile Asn 340 345 350 Ala Thr Asn Ile Lys His Phe Lys Asn
Cys Thr Ser Ile Ser Gly Asp 355 360 365 Leu His Ile Leu Pro Val Ala
Phe Arg Gly Asp Ser Phe Thr His Thr 370 375 380 Pro Pro Leu Asp Pro
Gln Glu Leu Asp Ile Leu Lys Thr Val Lys Glu 385 390 395 400 Ile Thr
Gly Phe Leu Leu Ile Gln Ala Trp Pro Glu Asn Arg Thr Asp 405 410 415
Leu His Ala Phe Glu Asn Leu Glu Ile Ile Arg Gly Arg Thr Lys Gln 420
425 430 His Gly Gln Phe Ser Leu Ala Val Val Ser Leu Asn Ile Thr Ser
Leu 435 440 445 Gly Leu Arg Ser Leu Lys Glu Ile Ser Asp Gly Asp Val
Ile Ile Ser 450 455 460 Gly Asn Lys Asn Leu Cys Tyr Ala Asn Thr Ile
Asn Trp Lys Lys Leu 465 470 475 480 Phe Gly Thr Ser Gly Gln Lys Thr
Lys Ile Ile Ser Asn Arg Gly Glu 485 490 495 Asn Ser Cys Lys Ala Thr
Gly Gln Val Cys His Ala Leu Cys Ser Pro 500 505 510 Glu Gly Cys Trp
Gly Pro Glu Pro Arg Asp Cys Val Ser Cys Arg Asn 515 520 525 Val Ser
Arg Gly Arg Glu Cys Val Asp Lys Cys Asn Leu Leu Glu Gly 530 535 540
Glu Pro Arg Glu Phe Val Glu Asn Ser Glu Cys Ile Gln Cys His Pro 545
550 555 560 Glu Cys Leu Pro Gln Ala Met Asn Ile Thr Cys Thr Gly Arg
Gly Pro 565 570 575 Asp Asn Cys Ile Gln Cys Ala His Tyr Ile Asp Gly
Pro His Cys Val 580 585 590 Lys Thr Cys Pro Ala Gly Val Met Gly Glu
Asn Asn Thr Leu Val Trp 595 600 605 Lys Tyr Ala Asp Ala Gly His Val
Cys His Leu Cys His Pro Asn Cys 610 615 620 Thr Tyr Gly Cys Thr Gly
Pro Gly Leu Glu Gly Cys Pro Thr Asn Gly 625 630 635 640 Pro Lys Ile
Pro Ser Ile Ala Thr Gly Met Val Gly Ala Leu Leu Leu 645 650 655 Leu
Leu Val Val Ala Leu Gly Ile Gly Leu Phe Met Arg Arg Arg His 660 665
670 Ile Val Arg Lys Arg Thr Leu Arg Arg Leu Leu Gln Glu Arg Glu Leu
675 680 685 Val Glu Pro Leu Thr Pro Ser Gly Glu Ala Pro Asn Gln Ala
Leu Leu 690 695 700 Arg Ile Leu Lys Glu Thr Glu Phe Lys Lys Ile Lys
Val Leu Gly Ser 705 710 715 720 Gly Ala Phe Gly Thr Val Tyr Lys Gly
Leu Trp Ile Pro Glu Gly Glu 725 730 735 Lys Val Lys Ile Pro Val Ala
Ile Lys Glu Leu Arg Glu Ala Thr Ser 740 745 750 Pro Lys Ala Asn Lys
Glu Ile Leu Asp Glu Ala Tyr Val Met Ala Ser 755 760 765 Val Asp Asn
Pro His Val Cys Arg Leu Leu Gly Ile Cys Leu Thr Ser 770 775 780 Thr
Val Gln Leu Ile Thr Gln Leu Met Pro Phe Gly Cys Leu Leu Asp 785 790
795 800 Tyr Val Arg Glu His Lys Asp Asn Ile Gly Ser Gln Tyr Leu Leu
Asn 805 810 815 Trp Cys Val Gln Ile Ala Lys Gly Met Asn Tyr Leu Glu
Asp Arg Arg 820 825 830 Leu Val His Arg Asp Leu Ala Ala Arg Asn Val
Leu Val Lys Thr Pro 835 840 845 Gln His Val Lys Ile Thr Asp Phe Gly
Leu Ala Lys Leu Leu Gly Ala 850 855 860 Glu Glu Lys Glu Tyr His Ala
Glu Gly Gly Lys Val Pro Ile Lys Trp 865 870 875 880 Met Ala Leu Glu
Ser Ile Leu His Arg Ile Tyr Thr His Gln Ser Asp 885 890 895 Val Trp
Ser Tyr Gly Val Thr Val Trp Glu Leu Met Thr Phe Gly Ser 900 905 910
Lys Pro Tyr Asp Gly Ile Pro Ala Ser Glu Ile Ser Ser Ile Leu Glu 915
920 925 Lys Gly Glu Arg Leu Pro Gln Pro Pro Ile Cys Thr Ile Asp Val
Tyr 930 935 940 Met Ile Met Val Lys Cys Trp Met Ile Asp Ala Asp Ser
Arg Pro Lys 945 950 955 960 Phe Arg Glu Leu Ile Ile Glu Phe Ser Lys
Met Ala Arg Asp Pro Gln 965 970 975 Arg Tyr Leu Val Ile Gln Gly Asp
Glu Arg Met His Leu Pro Ser Pro 980 985 990 Thr Asp Ser Asn Phe Tyr
Arg Ala Leu Met Asp Glu Glu Asp Met Asp 995 1000 1005 Asp Val Val
Asp Ala Asp Glu Tyr Leu Ile Pro Gln Gln Gly Phe 1010 1015 1020 Phe
Ser Ser Pro Ser Thr Ser Arg Thr Pro Leu Leu Ser Ser Leu 1025 1030
1035 Ser Ala Thr Ser Asn Asn Ser Thr Val Ala Cys Ile Asp Arg Asn
1040 1045 1050 Gly Leu Gln Ser Cys Pro Ile Lys Glu Asp Ser Phe Leu
Gln Arg 1055 1060 1065 Tyr Ser Ser Asp Pro Thr Gly Ala Leu Thr Glu
Asp Ser Ile Asp 1070 1075 1080 Asp Thr Phe Leu Pro Val Pro Glu Tyr
Ile Asn Gln Ser Val Pro 1085 1090 1095 Lys Arg Pro Ala Gly Ser Val
Gln Asn Pro Val Tyr His Asn Gln 1100 1105 1110 Pro Leu Asn Pro Ala
Pro Ser Arg Asp Pro His Tyr Gln Asp Pro 1115 1120 1125 His Ser Thr
Ala Val Gly Asn Pro Glu Tyr Leu Asn Thr Val Gln 1130 1135 1140 Pro
Thr Cys Val Asn Ser Thr Phe Asp Ser Pro Ala His Trp Ala 1145 1150
1155 Gln Lys Gly Ser His Gln Ile Ser Leu Asp Asn Pro Asp Tyr Gln
1160 1165 1170 Gln Asp Phe Phe Pro Lys Glu Ala Lys Pro Asn Gly Ile
Phe Lys 1175 1180 1185 Gly Ser Thr Ala Glu Asn Ala Glu Tyr Leu Arg
Val Ala Pro Gln 1190 1195 1200 Ser Ser Glu Phe Ile Gly Ala 1205
1210 20120PRTArtificialheavy chain variable domain VH of anti-HER1
antibody GA201 20Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys
Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly
Phe Thr Phe Thr Asp Tyr 20 25 30 Lys Ile His Trp Val Arg Gln Ala
Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Tyr Phe Asn Pro Asn
Ser Gly Tyr Ser Thr Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val
Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu
Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95
Ala Arg Leu Ser Pro Gly Gly Tyr Tyr Val Met Asp Ala Trp Gly Gln 100
105 110 Gly Thr Thr Val Thr Val Ser Ser 115 120
21108PRTArtificiallight chain variable domain VL of anti-HER1
antibody GA201 21Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser
Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser
Gln Gly Ile Asn Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro
Gly Lys Ala Pro Lys Arg Leu Ile 35 40 45 Tyr Asn Thr Asn Asn Leu
Gln Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly
Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp
Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Phe Pro Thr 85 90 95
Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr 100 105
* * * * *